Document:

Supply Agreement

 EXHIBIT 10.2 
 CONFIDENTIAL TREATMENT 
 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED WITH “[CONFIDENTIAL TREATMENT REQUESTED].” AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 SUPPLY AGREEMENT 
 THIS SUPPLY
AGREEMENT (this “Agreement”), dated as of December 21, 2007 (the “Effective Date”), is made by and between CELL THERAPEUTICS, INC., a Washington corporation (“Buyer”), and BIOGEN IDEC INC., a
Delaware corporation (“Manufacturer”). 
 WHEREAS, pursuant to that certain Asset Purchase Agreement, dated as of
August 15, 2007, by and between Buyer and Manufacturer (the “Asset Purchase Agreement”), Buyer has purchased certain assets (the “Acquisition”) from Manufacturer relating to the Product (as defined the Asset
Purchase Agreement); and 
 WHEREAS, in connection with the Acquisition, upon the terms and subject to the conditions set forth herein, Buyer
desires to engage Manufacturer to (i) manufacture and supply Finished US Goods (as defined below) and (ii) provide Buyer with an appropriate opportunity to establish its own capabilities to manufacture Bulk Product (as defined below) and
supply Finished US Goods, whether directly or through a third Person. 
 NOW, THEREFORE, in consideration of the premises and mutual
covenants contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Buyer and Manufacturer agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Section 1.1 Definitions. As used in this Agreement, the following terms shall have the meanings ascribed to them below (note: terms used but
not otherwise defined herein shall have their respective meanings as set forth in the Asset Purchase Agreement): 
 “Acquisition” has the meaning set forth in the recitals. 
 “Affiliate” means, with respect to any
Person, any other Person that directly or indirectly Controls, is Controlled by or is under common Control with such first Person. A Person will be deemed to “Control” another Person if such first Person has the power to direct or
cause the direction of the management and policies of such other Person, whether through ownership of securities, by contract or otherwise. 
 “Agreement” has the meaning set forth in the introductory paragraph. 
 “Asset Purchase Agreement”
has the meaning set forth in the recitals. 
 “Bulk Product” means the Product in refrigerated liquid bulk form or such
other form as the parties may agree, but not in final dosage and not Finished US Goods. 

 CONFIDENTIAL TREATMENT 
 “Buyer” has the meaning set forth in the introductory paragraph. 
 “Buyer Indemnified Parties” has the meaning set forth in the Asset Purchase Agreement. 
 “Buyer NDC Number” has the meaning set forth in Section 7.11. 
 “cGMP Requirements” mean the FDA’s current good manufacturing practice requirements as promulgated under the FFDCA at 21 C.F.R.
(parts 210 and 211), and as further defined by FDA guidance documents, as such may be amended from time to time. 
 “COA”
means a certificate of analysis, including a certification of manufacture in accordance with cGMP Requirements and any deviations therefrom. 
 “Confidential Information” means information which is confidential or proprietary to the Disclosing Party, including know-how, scientific information, the terms of this Agreement, clinical data, efficacy and safety data,
adverse event information, formulas, methods and processes, specifications, pricing information (including discounts, rebates and other price adjustments) and other terms and conditions of sales, customer information, business plans and all other
intellectual property; provided, however, that Confidential Information shall not include the following: (i) information of a Disclosing Party that is known to a Receiving Party or its Affiliates prior to the time of disclosure to
it, to the extent evidenced by written records or other competent proof, unless a proprietary interest in such information is transferred to the Disclosing Party pursuant to this Agreement or the Asset Purchase Agreement; (ii) information that
is independently developed by employees, agents or independent contractors/subcontractors of a Receiving Party or its Affiliates without reference to or reliance upon the information furnished by the Disclosing Party, as evidenced by written records
or other competent proof, unless a proprietary interest in such information is transferred to the Disclosing Party pursuant to this Agreement or the Asset Purchase Agreement; (iii) information disclosed to a Receiving Party or its Affiliates by
a third Person that has a right to make such disclosure; or (iv) any other information that is or becomes part of the public domain through no fault or negligence of the Receiving Party. 
 “Confidentiality Agreement” has the meaning set forth in the Asset Purchase Agreement. 
 “Current Prescribing Information” means the prescribing information for the Product as in effect on the Effective Date (a copy of which
is attached to Exhibit A as Appendix 1 thereto). 
 “Disclosing Party” has the meaning set forth in
Section 10.1(a). 
 “Effective Date” has the meaning set forth in the introductory paragraph. 
 “FDA” means the United States Food and Drug Administration. 
 “FFDCA” means the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq., as amended. 
  

 2 

 CONFIDENTIAL TREATMENT 
 “Finished US Goods” mean either (i) packages (“Packages”)
of two (2) Kits (one In-111 Zevalin Kit and one Y-90 Zevalin Kit) labeled and ready for distribution and sale to end-users in the United States, with each such Package representing as of the Effective Date certain non-radioactive ingredients
necessary to produce one (1) treatment to a patient of the Product (i.e., a single dose of Indium-111 Ibritumomab Tiuxetan (referred to on the Current Prescribing Information as In-111 Zevalin) and Yttrium-90 Ibritumomab Tiuxetan
(referred to on the Current Prescribing Information as Y-90 Zevalin)), or (ii) individual Kits (either In-111 Zevalin Kits or Y-90 Zevalin Kits) labeled and ready for distribution and sale to end-users in the United States, all as more
particularly described on Exhibit A. Exhibit A, like the Current Prescribing Information, also notes required materials, in addition to Rituxan® (Rituximab), that are not part
of the Product, not supplied with the Kits or not available from Manufacturer or pursuant to this Agreement. 
 “Forecast”
has the meaning set forth in Section 3.1(b). 
 “FTE Rate” means, with respect to employees of Manufacturer, the
hourly rate of $175 (which is based upon 2,000 working hours in a year and an annual rate of $350,000); provided, however, that the FTE Rate shall be adjusted to take into account inflation on January 1, 2008 and the
first day of every calendar year during the Term thereafter by multiplying the applicable FTE Rate originally set forth above (without taking into account, if applicable, any previous adjustment) by a fraction, the numerator of which is the FTE
Index for the month of December of the previous year (e.g., December 2007) and the denominator of which is the FTE Index for December 2006. “FTE Index” means the Consumer Price Index for “All Urban Consumers”, U.S.
City Average, All Items, 1982-84=100 as listed at www.bls.gov (Series ID: CUUR0000SA0), which is the United States Department of Labor’s web site. In the event that such FTE Index ceases to be published or is significantly changed following
December 2006, then the parties shall negotiate in good faith to select an appropriate successor index for the remainder of the Term. 
 “Governmental Entity” means any court, administrative agency or commission or other governmental or regulatory authority or instrumentality of applicable jurisdiction, whether domestic or foreign. 
 “Governmental Rule” means any applicable law, judgment, order, award, decree, statute, ordinance, rule or regulation issued or
promulgated by any Governmental Entity. 
 “In-111 Zevalin Kit” has the meaning set forth in the definition of Kit.

 “Incremental Cost” shall mean the difference between the Manufacturing Cost Plus [CONFIDENTIAL TREATMENT
REQUESTED] for Finished US Goods resulting from the process used prior to the implementation of a Required Change (or, as applicable, a Proposed Change) and the Manufacturing Cost Plus [CONFIDENTIAL TREATMENT REQUESTED] for Finished US
Goods resulting from the process that includes such Required Change (or, as applicable, such Proposed Change), including in each instance (in the calculation of Manufacturing Cost) the fees and costs charged to Manufacturer and its Affiliates by any
non-Affiliated subcontractors. 
  

 3 

 CONFIDENTIAL TREATMENT 
 “Kit” means a kit to make a single dose, as part of one (1) treatment to a
patient, of (i) Indium-111 Ibritumomab Tiuxetan (referred to on the Current Prescribing Information as In-111 Zevalin) (an “In-111 Zevalin Kit”) or (ii) Yttrium-90 Ibritumomab Tiuxetan (referred to on the Current
Prescribing Information as Y-90 Zevalin) (a “Y-90 Zevalin Kit”), all as more particularly described on Exhibit A. Exhibit A, like the Current Prescribing Information, also notes required materials, in addition to
Rituxan® (Rituximab), that are not part of the Product, not supplied with the Kits or not available from Manufacturer or pursuant to this Agreement. 
 “Liabilities” mean any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, matured or
unmatured or determined or determinable, including those arising under any Governmental Rule, Contract or otherwise. 
 “Losses” mean any and all damages, losses, Taxes, Liabilities, claims, judgments, penalties, costs and expenses, including reasonable attorneys’ fees and litigation expenses. 
 “Manufacturer” has the meaning set forth in the introductory paragraph. 
 “Manufacturer Broader Changes” has the meaning set forth in Section 7.5(b). 
 “Manufacturing Confidential Information” means Confidential Information relating to the manufacture or supply of Bulk Product or
Finished US Goods (including Product Manufacturing Technology) that is (i) disclosed to Buyer or any of its Affiliates by Manufacturer or any of its Affiliates or subcontractors (including through observation by Buyer or any of its Affiliates)
and (ii) maintained as confidential by Manufacturer, its Affiliates or any such subcontractor prior to such disclosure; provided, however, that Manufacturing Confidential Information shall not include (x) information
disclosed to Buyer or any of its Affiliates by a third Person (excluding, for this purpose, Manufacturer, its Affiliates and its subcontractors and assignees) that has a right to make such disclosure or (y) any other information that is or
becomes part of the public domain through no fault or negligence of Buyer or any of its Affiliates or any third party manufacturer engaged by Buyer or any of its Affiliates. 
 “Manufacturing Cost” means the costs to produce any Finished US Goods at issue, as reasonably determined by Manufacturer, to the extent
that such costs would ordinarily be included as a “Cost of Goods Sold” under United States generally accepted accounting principles for a similar product as applied by Manufacturer on a basis consistent with Manufacturer’s historical
practice, including labor and material costs, allocable depreciation and amortization, product quality assurance/control costs, allocable facilities costs (e.g., sewer, water, property taxes), third party intellectual property payments
(including fees, royalties and milestone payments), insurance and other costs for transport, customs and duty clearance and storage of supplies or inventory. Without limitation, Manufacturing Cost for any Finished US Goods will include a
proportionate allocation (based upon the relative sales of the Product over the then preceding 12-month period in the United States versus such sales in the other jurisdictions for which Manufacturer is supplying Product (e.g., Buyer’s
US sales versus Schering’s ex-US sales)) for the costs to produce any failed batches of Bulk Product, Finished US Goods or any portion thereof (including drug substance), but only in respect of batches failing for causes other than
Manufacturer’s failure to comply with the cGMP Requirements or the then current Regulatory Applications/Approvals. 
  

 4 

 CONFIDENTIAL TREATMENT 
 “Manufacturing Cost Plus [CONFIDENTIAL TREATMENT REQUESTED]” means, with respect to any Finished US Goods at issue, the Manufacturing
Cost for such Finished US Goods multiplied by [CONFIDENTIAL TREATMENT REQUESTED]. 
 “Manufacturing Documentation”
means any and all of the following that are specific to and necessary for the manufacture of Bulk Product and Finished US Goods: manufacturing process validation reports; manufacturing instructions; batch record templates; manufacturing standard
operating procedures; specifications and test methods for Bulk Product and Finished US Goods, raw materials and stability; standard operating procedures and specifications for packaging and packaging instructions; master formula; validation reports
(analytical, packaging and cleaning); stability data; and approved supplier lists. 
 “Manufacturing Supply Team” has the
meaning set forth in Section 7.9. 
 “Mid-Term Transfer Election” means an election by Buyer to initiate the
manufacturing transfer activities contemplated by Section 7.8 prior to the date which is thirty-six (36) months before the end of the Term with the goal of enabling Buyer to effect a transfer of the manufacture of Bulk Product and
supply of Finished US Goods for Buyer’s requirements from Manufacturer and its subcontractors to Buyer or to Buyer’s designee(s) so that Buyer (and/or Buyer’s designee(s)) could commence the manufacture of Bulk Product and the supply
of Finished US Goods no later than thirty-six (36) months after a Mid-Term Transfer Election, all as more fully set forth in Section 7.8(a); provided, however, that any such election (i) may be made by Buyer only
in circumstances where Buyer could otherwise terminate this Agreement due to the uncured breach of this Agreement by Manufacturer (pursuant to Section 8.2(a)(ii)) or pursuant to Article IX and (ii) shall be deemed to be in
lieu of Buyer’s right to terminate this Agreement based upon the circumstances at issue. For the avoidance of doubt, the provisions of Section 7.8(f) shall not apply to a Mid-Term Transfer Election or the manufacturing transfer
activities resulting therefrom. 
 “NDC Number” means either of the national drug code numbers associated with the Product
as of the Agreement Date, No. 64406-104-04 or No. 64406-103-03. 
 “Order Date” has the meaning set forth in
Section 3.1(d). 
 “Package” has the meaning set forth in the definition of Finished US Goods. 
 “Person” means any individual, corporation, partnership, limited liability company, joint venture, trust, business association,
organization, or other entity. 
 “Product” means the pharmaceutical
product currently marketed and sold as ZEVALIN® (Ibritumomab Tiuxetan), consisting of Indium-111 Ibritumomab Tiuxetan and Yttrium-90 Ibritumomab Tiuxetan. Further information regarding the
Product is set forth in the Current Prescribing Information, which information is incorporated herein by reference. 
 “Product
Intellectual Property” has the meaning set forth in the Asset Purchase Agreement. 
  

 5 

 CONFIDENTIAL TREATMENT 
 “Product Manufacturing Technology” means all trade secrets in the possession and under the control of Manufacturer or its Affiliates,
including research and development, formulae, test procedures, manufacturing procedures, Bulk Product and Finished US Goods formulations or other technical or proprietary information and knowledge, whether or not patentable, to the extent
(a) either (i) necessary for, or used by Manufacturer or its Affiliates in, the manufacture of Bulk Product or Finished US Goods or (ii) provided or made available by Manufacturer or its Affiliates to Manufacturer’s
subcontractors for purposes of supplying Finished US Goods in connection with their further manufacturing activities in respect of Bulk Product or Finished US Goods, and (b) in existence and owned by, or licensed to and controlled by,
Manufacturer as of immediately prior to the date of the completion of the manufacturing transfer contemplated by Section 7.8 (excluding, in any event, any plant, tangible property or equipment). As of the Effective Date (i.e., as
if the date of the completion of the manufacturing transfer contemplated by Section 7.8 were the Effective Date), no such in-licensed Product Manufacturing Technology exists. Notwithstanding any provision herein to the contrary, Product
Manufacturing Technology shall not include any item of intellectual property or any intellectual property right that is or was an actual or potential subject (regardless of any territorial limitation) for a grant of rights under any Sublicense
Agreement (as defined in the Asset Purchase Agreement). 
 “Proposed Change” has the meaning set forth in
Section 7.5(a). 
 “Proposing Party” has the meaning set forth in Section 7.5(a). 
 “Quality Agreement” means that agreement in the form attached hereto as Exhibit B that describes the parties’ respective
quality control, quality assurance and regulatory responsibilities relating to the manufacture and delivery of Finished US Goods by Manufacturer to Buyer, as amended or restated from time to time upon the written approval of the parties. To the
extent of any conflict or inconsistency between the provisions of the Quality Agreement and this Agreement, the provisions of this Agreement shall control. 
 “Recipient” has the meaning set forth in Section 7.5(a). 
 “Receiving
Party” has the meaning set forth in Section 10.1(a). 
 “Regulatory Applications/Approvals” mean
Biologics License Application No. 125019, as initially approved by the FDA on February 19, 2002, and all supplements, amendments and revisions thereto, whether approved or not, together with all annual reports with respect thereto.

 “Replacement Source” has the meaning set forth in Section 7.8(e). 
 “Replacement Source Approval” has the meaning set forth in Section 7.8(e). 
 “Required Change” has the meaning set forth in Section 7.4. 
 “Seller Indemnified Parties” has the meaning set forth in the Asset Purchase Agreement. 
  

 6 

 CONFIDENTIAL TREATMENT 
 “Short-Dated Product” means (i) In-111 Zevalin Kits with expiry dates in December 2008 or March 2009 and (ii) Y-90 Zevalin
Kits with expiry dates in March 2009. 
 “Specifications” mean, for Bulk Product and for Finished US Goods, (i) the
requirements and standards for Bulk Product and Finished US Goods set forth on Exhibit C attached hereto, as amended or supplemented in accordance with Sections 7.4 or 7.5, or (ii) any variations thereto agreed to in
writing by the parties (including in situations where the parties anticipate the making of a change in approved Specifications pursuant to activities contemplated by Sections 7.4 or 7.5). 
 “Tax” means all domestic and foreign taxes and assessments, including all interest, penalties and additions with respect thereto.

 “Term” has the meaning set forth in Section 8.1. 
 “Transaction Document” has the meaning set forth in the Asset Purchase Agreement. 
 “United States” has the meaning set forth in the Asset Purchase Agreement. 
 “Y-90 Zevalin Kit” has the meaning set forth in the definition of Kit. 
 Section 1.2 Interpretation. 
 (a) When used in this Agreement, the words “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation.” 
 (b) Any terms defined in the singular shall have a comparable meaning when used in the plural, and vice-versa. 
 (c) All references to any introductory paragraph, recitals, Articles, Sections, Exhibits and Schedules shall be deemed references to the
introductory paragraph, recitals, Articles, Sections, Exhibits and Schedules to this Agreement unless otherwise specifically set forth herein. 
 (d) This Agreement shall be deemed drafted jointly by Buyer and Manufacturer and shall not be specifically construed against either party based on any claim that such party or its counsel drafted this Agreement.

 ARTICLE II 
 ENGAGEMENT 

 Section 2.1 Engagement to Manufacture and Supply. During the Term and upon the terms and subject to the conditions of this
Agreement and the Quality Agreement, Buyer hereby agrees to purchase, and Manufacturer hereby agrees to supply, whether from inventory or otherwise, all of the requirements of Buyer (as well as Buyer’s licensees, successors and assignees) for
Finished US Goods to be ultimately used by or sold to end-users in the United 

  

 7 

 CONFIDENTIAL TREATMENT 
 States. Buyer acknowledges and agrees that: (i) in the absence of the establishment of a Replacement Source following a Mid-Term Transfer Election, Buyer shall purchase all of such requirements for Finished US
Goods during the Term (as well, if applicable, as any other form of Product or portion thereof) exclusively from Manufacturer as more specifically set forth herein, other than limited amounts of Finished US Goods which may be procured from a
Replacement Source in the process of such Replacement Source being established in accordance with Section 7.8; and (ii) Manufacturer’s foregoing engagement is not to the exclusion of any other activities of Manufacturer
(including the manufacture and distribution of other products by Manufacturer, as well as the manufacture and supply of Bulk Product or finished goods incorporating such Bulk Product to be ultimately used by or sold to end-users outside the United
States). Notwithstanding any provision herein to the contrary, Manufacturer shall be entitled to use subcontractors for the purpose of fulfilling its obligations under this Agreement; provided, however, that Manufacturer shall not be
relieved of its responsibilities or obligations under this Agreement as a result thereof. For the avoidance of doubt, in those cases where Manufacturer is to require specified conduct of its subcontractor, Manufacturer’s obligation under this
Agreement is acknowledged to include such subcontractor actually conforming to such specified conduct. 
 Section 2.2 Batch
Release. Buyer shall be solely responsible for the batch release of all Finished US Goods (as well, if applicable, as any other form of Product or portion thereof) into the United States market, including as to the distribution to, and use by,
any and all end users in the United States; provided, however, that Buyer is entitled to rely on COAs and other Manufacturing Documentation provided hereunder by Manufacturer, as well as Manufacturer’s representations,
warranties and covenants under Article IV and Article V. Nothing in the foregoing sentence is intended to relieve Manufacturer of responsibility, with respect to Bulk Product or Finished US Goods, for its provision of inaccurate COAs
or other Manufacturing Documentation nor the breach of such representations, warranties and covenants. 
 Section 2.3 Supply
Chain. Manufacturer shall not be required at any time to take physical possession of Finished US Goods (or in-process Finished US Goods) other than for testing and release purposes and Buyer shall provide Manufacturer with “ship-to”
instructions, including alternate instructions for storage of in-process Finished US Goods, for each step in the supply chain leading from Bulk Product to Finished US Goods so that Manufacturer’s subcontractors can be informed and directed
appropriately. 
 ARTICLE III 
 ORDERS AND DELIVERY 
 Section 3.1 Forecasting and Committed Orders. 
 (a) Concurrent with the execution of this Agreement, Buyer is submitting a purchase order previously reviewed and approved by Manufacturer
for the purchase of Packages and Kits. Such purchase order contains two (2) distinct lots of packages and kits, one of which shall be delivered within thirty (30) days of the Effective Date and the other of which shall be delivered within
ninety (90) days of the Effective Date. 
  

 8 

 CONFIDENTIAL TREATMENT 
 (b) In order to assist in the planning of production runs for Bulk Product and Finished US Goods, Buyer shall, on or before each
May 31 and November 30 during the Term, provide Manufacturer with Buyer’s forecasted requirement for Packages and Kits (a “Forecast”) for each half-year period (i.e., July 1 through December 31 and
January 1 through June 30) over the course of the then immediately following six (6) half-year periods (i.e., the forecast due by November 30, 2007 will cover the period of six (6) half-years, or thirty-six
(36) months, from January 1, 2008 through December 31, 2010) or, if less, through the end of the Term. Buyer shall forecast and order (except for the order contemplated by Section 3.1(a)) in amounts of at least 150
Packages (or 300 Kits, with each Package counting for this purpose as two Kits) in respect of 2008, 2009 and 2010, and of at least 250 Packages (or 500 Kits, with each Package counting for this purpose as two Kits) thereafter during the Term. Each
Forecast shall be made by Buyer in good faith, taking into account reasonable projections of demand for Packages (including allowance for reasonable safety stock). 
 (c) As to each Forecast: (i) any forecasted requirement for a period that is thirty (30) months or more into the forecasted
period (i.e., the sixth half-year period covered by such Forecast) shall be advisory only; (ii) any forecasted requirement for a period that is eighteen (18) months or more, but less than thirty (30) months, into the forecasted
period (i.e., the fourth and fifth half-year periods covered by such Forecast) may change by a factor of up to fifty percent (50%) in terms of total Kits (with each Package counting for this purpose as two Kits), up or down, in the next
Forecast (but no more); and (iii) any forecasted requirement for a period that is six (6) months or more, but less than eighteen (18) months, into the forecasted period (i.e., the second and third half-year periods covered by
such Forecast) may change by a factor of up to twenty-five percent (25%) in terms of total Kits (with each Package counting for this purpose as two Kits), up or down, in the next Forecast (but no more); provided, however, that
notwithstanding the foregoing, prior to the Forecast which includes the period of January 1, 2009 through June 30, 2009 as the first half-year period covered by such Forecast (i.e., the Forecast which is due prior to
November 30, 2008), all Forecasts delivered by Buyer shall be strictly for Manufacturer’s information (although prepared by Buyer in good faith), and shall not be binding on Buyer. Except as provided in the foregoing sentence, each
Forecast shall represent the amount of Packages and Kits to which Buyer is committed hereunder for any period at issue. 
 (d)
Each Forecast shall: (i) specifically refer to this Agreement; (ii) be accompanied by Buyer’s order for an amount of Packages and Kits as set forth for the first half-year covered by such Forecast (i.e., the Forecast delivered
on or before November 30, 2008 shall include Buyer’s order for the period from January 1, 2009 through June 30, 2009); and (iii) indicate Buyer’s requested delivery date(s) during the half-year at issue, the delivery
address, the transportation method and carrier and any special instructions requested. Each Forecast (as well as Buyer’s accompanying order) shall be delivered to such location as Manufacturer designates in writing to Buyer from time to time.
The date an order is deemed placed (the “Order Date”) shall be the date that Manufacturer actually receives the order form containing such order (as well as the accompanying Forecast). Without limiting the provisions of
Section 3.1(c): (x) each order shall be a firm order; and (y) Buyer shall not place orders more frequently than twice per year (i.e., as will result from the delivery of Forecasts twice a year accompanied by Buyer’s
order for the amount of Packages and Kits as set forth for the first half-year covered by each such Forecast). 
  

 9 

 CONFIDENTIAL TREATMENT 
 (e) Notwithstanding the foregoing provisions of Section 3.1(d), Manufacturer shall not be required to deliver any Kits or
Packages: (i) more frequently than once during each half-year period at issue; (ii) in quantities of less than 150 Packages (or 300 Kits, with each Package counting for this purpose as two Kits) in respect of 2008, 2009 and 2010, and of
less than 250 Packages (or 500 Kits, with each Package counting for this purpose as two Kits) thereafter during the Term; or (iii) less than six (6) months after the Order Date. 
 (f) Buyer’s forecasted requirements, as well as Buyer’s actual orders, for each of 2008, 2009 and 2010 shall be for at least six
hundred (600) Packages (or twelve hundred (1,200) Kits, with each Package counting for this purpose as two (2) Kits). 
 (g) In addition to orders resulting from Forecasts as provided in this Section 3.1, Buyer may submit additional orders (“Supplemental Orders”) in tandem with any Forecast-generated order. Manufacturer shall not
be obligated to accept, but shall consider in good faith whether to accept, any such Supplemental Order. Following receipt of a Supplemental Order, Manufacturer may, in Manufacturer’s sole discretion, identify additional terms and conditions
(including as to pricing and delivery) that would be a necessary part of any acceptance of such Supplemental Order by Manufacturer (to which Buyer may agree or respond by withdrawing the Supplemental Order at issue). 
 (h) Manufacturer, in its sole discretion, may reject any order that does not comply with this Agreement. Each order in compliance with the
requirements of this Agreement (including this Section 3.1) shall be deemed accepted by Manufacturer unless Manufacturer provides notification of rejection to Buyer within fifteen (15) business days of the applicable Order Date;
provided, however, that any Supplemental Order (as modified by additional terms and conditions identified by Manufacturer pursuant to Section 3.1(g)) must be expressly accepted by Manufacturer in writing within such fifteen
(15) day period, or it will be deemed rejected. 
 (i) Notwithstanding anything to the contrary contained in this
Agreement, Manufacturer’s obligation to supply Finished US Goods in response to an accepted order shall be only to use the same diligence in its efforts to manufacture and supply Finished US Goods to Buyer pursuant to this Agreement that
Manufacturer uses to manufacture and supply like products for itself and its Affiliates. 
 Section 3.2 Delivery of Finished US
Goods. 
 (a) Manufacturer shall not be liable for any delay in the delivery of Finished US Goods as long as Manufacturer
is in compliance with its obligations under Section 3.1(i); provided, however, that in the event that the actual delivery with respect to any accepted order delivered to Manufacturer pursuant to Section 3.1(d)
is more than ninety (90) days late (so long as the “timely” delivery date at issue is not earlier than six (6) months after the applicable Order Date), any such delay may, at Buyer’s election made within thirty
(30) days of the triggering event, be deemed a material breach of this Agreement solely for purposes of Sections 7.8(f) and 8.2(a)(ii). 
  

 10 

 CONFIDENTIAL TREATMENT 
 (b) A COA shall accompany each shipment of Finished US Goods in the form attached hereto as Exhibit D. 
 (c) Manufacturer may commence shipment as to any accepted order prior to the completion of such order in full. 
 (d) All Finished US Goods shipped under this Agreement shall be shipped F.O.B. the manufacturing site to such location in the United
States designated by Buyer in the applicable accepted order. Buyer shall pay all freight, insurance charges, Taxes, levies, import and export duties, inspection fees and other charges applicable to the sale and transport of Finished US Goods;
provided, however, that Buyer shall not be liable for any Taxes to the extent payable or assessed based upon the income or worth of Manufacturer. Title and risk of loss and damages to Finished US Goods shall pass to Buyer (and delivery
to Buyer shall be deemed to occur) upon delivery to the carrier at the manufacturing site. In the event of damage or loss to Finished US Goods after delivery to the carrier, Buyer shall be responsible to file claims with the carrier. Manufacturer
shall cooperate with Buyer in the filing of such claims. 
 (e) Each shipment of Finished US Goods to Buyer shall constitute a
separate sale, obligating Buyer to pay therefor, whether such shipment is in whole or only partial fulfillment of any order or confirmation issued in connection therewith. 
 Section 3.3 Price for Finished US Goods. 
 (a) The price payable by Buyer for Finished US Goods shall be the Manufacturing Cost Plus [CONFIDENTIAL TREATMENT REQUESTED]. 
 (b) Without limiting the calculation of the Manufacturing Cost for any Finished US Goods at issue, the price payable by Buyer shall be
adjusted pursuant to the change control procedures provided in Sections 7.4 and 7.5. 
 Section 3.4 Change in
Branding. Notwithstanding anything herein to the contrary, and in addition to the pricing otherwise set forth in Section 3.3, in respect of any activities associated with a change in packaging to reflect Buyer’s name, trademarks
or other branding, Buyer shall, promptly following Manufacturer’s delivery to Buyer from time to time of itemized invoices for the same: (i) reimburse Manufacturer and its subcontractors for (x) all third party costs or expenses
reasonably incurred by Manufacturer or its subcontractors with respect to such activities and (y) the actual costs of all supplies reasonably provided by Manufacturer or its subcontractors with respect to such activities; and (ii) pay
Manufacturer and its subcontractors for time reasonably spent by their personnel on such activities at the FTE Rate. 
 ARTICLE IV 

REPRESENTATIONS AND WARRANTIES 
 Section 4.1 Authority. Each party hereby represents and warrants to the other party that (i) it has the requisite power and authority to enter into this Agreement and (ii) the execution and delivery of this Agreement
by it have been duly and validly authorized. 
  

 11 

 CONFIDENTIAL TREATMENT 
 Section 4.2 Manufacturer’s Representations and Warranties. Manufacturer hereby represents and warrants that during the Term: 

(a) it will (or will require its subcontractors to) use raw materials in the manufacture of Bulk Product and Finished US Goods that
conform to applicable Specifications, as verified in accordance with the testing standards and procedures specified therein; 
 (b) Finished US Goods, when delivered by Manufacturer to Buyer hereunder, will have at least eighteen (18) months remaining until their expiry date, except (i) that any Finished US Goods ordered by Buyer pursuant to
Section 3.1(a) will be Short-Dated Product or (ii) to the extent Buyer agrees otherwise; 
 (c) each COA shall
accurately reflect the values reported thereon; 
 (d) it will (or will require its subcontractors to) manufacture Bulk
Product and Finished US Goods hereunder in accordance with applicable cGMP Requirements and the Specifications; 
 (e) it will
not use for its performance hereunder any employee, consultant or contractor that has been debarred by the FDA or, to its knowledge, is the subject of debarment proceedings by the FDA; and 
 (f) it will maintain such records as are necessary and appropriate to demonstrate compliance in the manufacturing of Bulk Product and
Finished US Goods with applicable cGMP Requirements for a period of not less than twenty-four (24) months from the expiration date of each batch of Finished US Goods, or such longer period as may be required by Governmental Rule. 
 Section 4.3 Disclaimer of Warranties. THE PROVISIONS OF THIS ARTICLE IV ARE MANUFACTURER’S SOLE REPRESENTATIONS AND WARRANTIES
RELATED TO THIS AGREEMENT OR THE MANUFACTURE, SUPPLY, USE OR SALE OF BULK PRODUCT OR FINISHED US GOODS AND ARE MADE IN LIEU OF (AND MANUFACTURER DISCLAIMS) ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTIES OF QUALITY, PERFORMANCE,
MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE, AS WELL AS WARRANTIES WITH RESPECT TO LACK OF THIRD PARTY INFRINGEMENT, THAT MAY RESULT FROM THIS AGREEMENT OR THE MANUFACTURE, SUPPLY, USE OR SALE OF BULK PRODUCT OR FINISHED US GOODS.

 ARTICLE V 
 CERTAIN
MANUFACTURING STANDARDS AND MATTERS 
 Section 5.1 Stability Studies. Manufacturer shall conduct or have conducted stability
studies at least one (1) time each year (to the extent annual testing is required by the FDA or the Regulatory Applications/Approvals) for at least one (1) batch of Finished US Goods from each site where Finished US Goods are manufactured.
Manufacturer shall provide Buyer with an annual report of the results from such stability studies which occur during the year preceding the report. 
  

 12 

 CONFIDENTIAL TREATMENT 
 Section 5.2 Sampling Procedures; Reference Standards. 
 (a) Manufacturer shall retain samples of Finished US Goods from each batch for at least a period of one (1) year after the expiration
date of such batch. The sample size shall be twice the size necessary to conduct quality control testing. Upon Buyer’s written request, Manufacturer shall provide Buyer with up to one half (1/2) (in the aggregate) of the original amount of
the retained samples of Finished US Goods. 
 (b) In order to facilitate the prompt and efficient generation and exchange
between the parties of quality control data pertaining to Finished US Goods, Manufacturer shall, at Buyer’s request, send to Buyer test samples selected according to a sampling plan agreed between Manufacturer and Buyer before Manufacturer has
finished all of its testing for a particular batch. 
 (c) Promptly after each of Buyer’s written requests, Manufacturer
shall supply Buyer from time to time with sufficient amounts of reference standards for Finished US Goods and, as per Manufacturer’s current practice, the intermediates, impurities and degradation products of each for Buyer to perform
appropriate quality control testing related to Finished US Goods to which this Agreement applies. 
 Section 5.3 Cell Banks.
Manufacturer shall be responsible for the biological purity and maintenance of the master cell bank and any working cell banks maintained by Manufacturer, it being understood that no working cell bank is maintained as of the Effective Date for the
Product. This includes monitoring for viability by the procedures set forth in the Quality Agreement. Upon Buyer’s request, Manufacturer shall provide Buyer with any requested number of vials of viable cells from the master cell bank, together
with the thawing and storage protocols, within ninety (90) days of such request, but limited to an aggregate (combining all such requests) of twenty (20) vials (including any vials provided as part of a manufacturing transfer). From time
to time thereafter (i.e., after twenty (20) such vials have been provided in the aggregate), Manufacturer shall deliver to Buyer such additional vials of viable frozen cells from the master and any working cell banks as may be reasonably
requested within twenty-four (24) months of any such request. 
 Section 5.4 Costs. In respect of the performance by
Manufacturer of the activities contemplated by Sections 5.1, 5.2 and 5.3, Buyer shall, promptly following Manufacturer’s delivery to Buyer from time to time of itemized invoices for the same: (i) reimburse Manufacturer
for (x) all third party costs or expenses incurred by Manufacturer with respect to such activities and (y) Manufacturer’s actual costs of all supplies provided by Manufacturer with respect to such activities; and (ii) pay
Manufacturer for time spent by Manufacturer’s personnel on such activities at the FTE Rate. 
 Section 5.5
Rework/Reprocessing. Manufacturer shall conduct any rework or reprocessing activities with respect to Bulk Product or Finished US Goods manufacturing by using rework or reprocessing procedures, if any, that are: (i) referenced in
applicable 

  

 13 

 CONFIDENTIAL TREATMENT 
 Specifications; (ii) set forth in the Regulatory Applications/Approvals; and (iii) approved by Buyer in writing in advance, such approval not to be unreasonably withheld or delayed; provided,
however, that Manufacturer shall be entitled to implement (and Buyer shall be obligated to give effect to) Manufacturer Broader Changes affecting any such rework or reprocessing activities, in accordance with Section 7.5(d). Bulk
Product or Finished US Goods failing sterility testing shall not be reworked or reprocessed. 
 Section 5.6 Inspection and
Notice. 
 (a) Manufacturer shall provide Buyer with a copy of all notices in relation to Bulk Product or Finished US
Goods supply that Manufacturer receives from subcontractors that affect Bulk Product or Finished US Goods (including notices of regulatory inspections and the like). 
 (b) Buyer shall have the right, on reasonable advance notice and during normal business hours (but no more frequently than once per year),
to have its quality control or quality assurance personnel or representatives inspect and audit the facilities and operations of Manufacturer directly related to the manufacture and supply of Bulk Product and Finished US Goods in order to confirm
compliance with the covenants contained in this Agreement and, in the event that Manufacturer relies upon subcontractors to manufacture or supply Bulk Product or Finished US Goods, Manufacturer shall use commercially reasonable efforts to cause such
subcontractors to permit Buyer’s inspection and audit of their facilities directly responsible for the manufacture or supply of Bulk Product or Finished US Goods, on reasonable advance notice and during normal business hours (but no more
frequently than once per year); provided, however, that Manufacturer reserves the right to refuse access, or to cause or permit its subcontractors to refuse access, to any facilities where there is a material risk to health or safety
or to the security or quality of Bulk Product, Finished US Goods or any other product of Manufacturer or its subcontractors. Notwithstanding the foregoing limitations on the frequency of inspections and audits of Manufacturer and its subcontractors,
Buyer nevertheless shall be entitled to conduct such number of follow-up audits as may be reasonably necessary to ascertain the correction of any deficiency identified in a prior audit, whether such audit was conducted by or on behalf of Buyer, the
FDA, or other Governmental Entity. 
 (c) Manufacturer shall: (i) notify Buyer, as promptly as practicable, of any
inspection of its facilities used to manufacture or supply Bulk Product or Finished US Goods by any Governmental Entity which inspection relates specifically to the manufacture or supply of Bulk Product or Finished US Goods with the view towards
providing such notice to Buyer as to allow Buyer to be present to witness such inspection and any wrap-up or end of inspection meeting conducted between Manufacturer and such Governmental Entity; and (ii) furnish Buyer with copies of all
reports and analyses generated by any such inspection within seven (7) days of receipt (in addition to providing Buyer with a facsimile copy within seventy-two (72) hours). For the avoidance of doubt, Buyer’s attendance at any wrap-up
or end of inspection meeting between Manufacturer and a Governmental Entity shall be in the capacity of observer. If Buyer is in attendance at any inspection by a Governmental Entity, Manufacturer shall deliver to Buyer copies of inspection
observations and findings promptly upon their availability following the close of any such inspection or wrap-up or end of inspection meeting, as the case may be. 
  

 14 

 CONFIDENTIAL TREATMENT 
 (d) With respect to inspections by Governmental Entities at which Buyer is not present, Manufacturer shall (i) update Buyer as often
as reasonably practicable as to the progress of any such inspection and (ii) furnish Buyer with copies of all reports and analyses generated by any such inspection within seven (7) days of receipt. 
 Section 5.7 Buyer’s Covenants for Quality Assurance. Buyer hereby agrees, during the Term, that it shall: 
 (a) hold, store, handle, ship, deliver, distribute and sell all Finished US Goods (i) in accordance with applicable cGMP Requirements
and any Governmental Rules and (ii) in compliance with the Specifications; and 
 (b) enter into all necessary compliance
agreements as may be reasonably designated by Manufacturer upon reasonable, usual and customary terms and conditions, including agreements to cover adverse experience reporting and a pharmacovigilance agreement. 
 Section 5.8 Returns Requested by Manufacturer. Notwithstanding any other provisions of this Agreement, Buyer agrees, if so requested by
Manufacturer in writing, to return (or to cause to be returned) to Manufacturer, at Manufacturer’s expense, any Bulk Product (whether or not contained within Product) or Finished US Goods in the possession, or under the control, of Buyer that
are, or are claimed to be, defective, or otherwise to dispose of such Bulk Product and Finished US Goods as Manufacturer may direct. Buyer shall not be obligated to pay Manufacturer for, and Manufacturer shall be responsible for all costs associated
with the delivery and destruction of, such Bulk Product and Finished US Goods. 
 Section 5.9 Rejection by Buyer. Within thirty
(30) days of receipt of any shipment of Finished US Goods, Buyer shall, if it elects to do so, perform or cause to be performed samplings and tests using validated test methods described in the Regulatory Applications/Approvals to determine
whether the Finished US Goods in such shipment have been manufactured in conformity with applicable cGMPs Requirements and the Specifications. Any shipment of Finished US Goods not refused by Buyer on this basis within such 30-day period shall be
deemed accepted by Buyer. If Buyer wishes to refuse acceptance on this basis, Buyer shall, within such 30-day period, inform Manufacturer in writing of Buyer’s refusal to accept the shipment and the reason therefore (i.e., by identifying
the manner in which the manufacture of Finished US Goods in such shipment is not in conformity with applicable cGMPs Requirements and the Specifications). In the event that Buyer refuses acceptance of such shipment on such basis within such 30-day
period, Manufacturer, upon confirmation of the reasons for such refusal, shall either replace the defective Finished US Goods or refund the purchase price, as Manufacturer may elect in its sole discretion. If Manufacturer and Buyer do not agree on
such refusal, then any party may refer the matter for final analysis to a specialized laboratory of national reputation acceptable to both parties for the purpose of determining the results. Any determination by such laboratory shall be final and
binding upon the parties. If such laboratory determines that the manufacture of Finished US Goods in such shipment is not in conformity with applicable cGMPs Requirements and the Specifications, Manufacturer shall bear all expenses of shipping and
testing the shipment samples. Otherwise, Buyer shall bear all expenses of shipping and testing such shipment samples. Buyer shall not be obligated to pay for, and Manufacturer shall be responsible for all costs associated with, the delivery and
destruction of properly rejected Finished US Goods. For the avoidance of doubt, the parties agree that, except pursuant to the provisions of Section 5.8 or this Section 5.9, Buyer may not return any Finished US Goods to
Manufacturer. 
  

 15 

 CONFIDENTIAL TREATMENT 
 ARTICLE VI 
 PAYMENTS 
 Section 6.1 Invoices. Manufacturer shall send invoices to a single address specified in writing by Buyer, but not before the shipment to Buyer of the order to which it relates (if applicable). All payments
to be made hereunder shall be made by Buyer to Manufacturer within thirty (30) days after receipt of an invoice by electronic funds transmission, without any offset or deduction of any nature whatsoever, to such account as Manufacturer
specifies in writing to Buyer with written confirmation of payment sent by facsimile to such address as Manufacturer specifies in writing to Buyer. If Buyer fails to pay any invoiced amount when due, (i) a service charge shall be imposed by
Manufacturer equal to the lesser of one and one-half percent (1.5%) or the highest rate permitted by Governmental Rule of the outstanding amount for each month or portion thereof that such amount is overdue and (ii) Buyer shall reimburse
Manufacturer for all Losses incurred as part of any collection efforts. 
 Section 6.2 Taxes. Buyer shall bear solely the cost of
any Taxes of any kind, nature or description whatsoever applicable to or by reason of this Agreement, and Buyer shall forthwith pay to Manufacturer all such sums upon demand; provided, however, that Buyer shall not be liable for any
Taxes to the extent payable or assessed based upon the income or worth of Manufacturer. 
 ARTICLE VII 
 REGULATORY MATTERS; RECORDS 
 Section 7.1 Inspections. During the Term, Manufacturer shall be responsible for handling and responding to any FDA or other Governmental Entity inspections with respect to the manufacture or supply of Bulk Product or Finished US
Goods. Manufacturer shall provide to Buyer any information reasonably requested by Buyer and all information requested by any Governmental Entity concerning any such inspection. To the extent Manufacturer requires the assistance of Buyer in order to
fulfill its obligations pursuant to this Section 7.1, Buyer agrees to fully cooperate and assist Manufacturer at Buyer’s expense. 
 Section 7.2 Reporting. During the Term, Manufacturer shall be responsible for any reporting of matters regarding the manufacture or supply of Bulk Product or Finished US Goods to the FDA or other Governmental Entities, or Buyer,
as the case may be, in accordance with any Governmental Rules, except for any such matters that Buyer is required to report as the owner of any Regulatory Applications/Approvals, which matters Buyer shall report. If reported directly to the FDA or
other Governmental Entities, the party submitting the report shall furnish copies of all such reports to the other party within forty-eight (48) hours after submission to the FDA or any other Governmental Entities. Manufacturer shall also
advise Buyer of any occurrences or information that arise out of the manufacturing activities of Manufacturer that, to Manufacturer’s knowledge, have or could reasonably be expected to have adverse regulatory compliance or reporting
consequences concerning the Product. 
  

 16 

 CONFIDENTIAL TREATMENT 
 Section 7.3 Permits, Licenses and Approvals. During the Term, Manufacturer and its contractors shall have responsibility to maintain all
regulatory and governmental permits, licenses and approvals that are necessary for the manufacture of Bulk Product and the supply of Finished US Goods by Manufacturer pursuant to this Agreement; provided, however, that the parties
understand and agree that Buyer owns the Regulatory Applications/Approvals and, as a result, Buyer shall be responsible for any and all related filings required pursuant to this Section 7.3. Each party agrees that, to the extent required
to fulfill their respective obligations under this Section 7.3, such party shall reasonably cooperate and assist the other party at the requesting party’s expense (which shall be calculated at an FTE Rate for Manufacturer’s
cooperation). During the Term, Buyer shall be responsible for and shall pay all product and application fees related to the Product in the United States, including the manufacture or supply of Bulk Product or Finished US Goods at the facilities of
Manufacturer and its contractors and the distribution and sale of Finished US Goods. Buyer shall also be responsible for compliance with all Governmental Rules in the United States relating to the distribution and sale of the Product. For the
avoidance of doubt, Manufacturer and its contractors shall own and shall be responsible for all licenses, permits and filings relating to the basic operation of their manufacturing facilities and the payment of all related establishment license
fees. 
 Section 7.4 Required Changes in Specifications or Process. If Buyer or Manufacturer is required to change any
Specifications or the process used to manufacture or supply Bulk Product or Finished US Goods (i) in order to comply with any Governmental Rule, (ii) in response to the order or request of any Governmental Entity, (iii) due to the
loss of a validated source of a reagent or other raw materials or (iv) in order to avoid infringing any third party patent (each of the foregoing, a “Required Change”), all of the following provisions shall apply: 

(a) The party receiving any order or request from the Governmental Entity, or any notice of the loss of a validated source of a reagent
or other raw materials or of the infringement of any third party patent, shall promptly advise the other party in writing of any such Required Change(s) to Specifications or the process used to manufacture or supply Bulk Product or Finished US Goods
and each party shall promptly advise the other as to scheduling adjustments that may result from such Required Change(s), if any. 
 (b) Manufacturer shall exercise commercially reasonable efforts to implement all Required Changes to Specifications and the process used to manufacture or supply Bulk Product or Finished US Goods and to resume any resulting interruptions in
production schedules as soon as reasonably possible after notice thereof, but in any event shall do so within the time required by any Governmental Entity, if applicable. 
 (c) Buyer shall reimburse Manufacturer for the following, upon delivery by Manufacturer to Buyer from time to time of itemized invoices
for the same, to the extent incurred by Manufacturer or arising as part of Manufacturer’s efforts to implement any such Required Changes to Specifications or the process used to manufacture or supply Bulk Product or Finished US Goods:
(i) all third party costs or expenses; (ii) Manufacturer’s actual costs of all supplies provided by Manufacturer; and (iii) time spent by Manufacturer’s personnel at the FTE Rate (including with respect to activities
contemplated by Sections 7.4(a), 7.4(b) and 7.4(e)). 
  

 17 

 CONFIDENTIAL TREATMENT 
 (d) Without limiting the calculation of the Manufacturing Cost for any Finished US Goods at issue, Manufacturer may increase the pricing
for Finished US Goods under this Agreement to reflect the Incremental Cost of any Required Change. 
 (e) Buyer shall prepare
for submission, and Manufacturer shall review and provide comments upon, any regulatory filings required in relation to implementation of any Required Change other than those pertaining to any establishment license or other license or permit
necessary for the basic operation of the facilities in which the Bulk Product or Finished US Goods are manufactured. For the avoidance of doubt, Manufacturer shall prepare modifications to the CMC section of any Regulatory Applications/Approvals,
subject to review and amendment by Buyer, for inclusion in any amendment or modification by Buyer to the Regulatory Applications/Approvals necessitated by a Required Change. 
 Section 7.5 Discretionary Changes to Specifications, Process or Suppliers. 
 (a) If either party (the “Proposing Party”) desires to change Specifications or the process used to manufacture or supply
Bulk Product or Finished US Goods in way that does not involve a Required Change, it shall notify the other party (the “Recipient”) in writing of the proposed change (a “Proposed Change”), and the Manufacturing
Supply Team shall review and discuss such Proposed Change, including whether the implementation of such Proposed Change is expected to result in material additional costs over what Manufacturer is then incurring to manufacture or supply Bulk Product
or Finished US Goods. 
 (b) Manufacturer shall be entitled to propose, as Proposed Changes, the following
(“Manufacturer Broader Changes”): (i) changes to, among or within the manufacturing facilities of Manufacturer or its contractors (including changes to general equipment or any facility-wide standard operating procedures, other
general changes to or within a facility, or any shifting of activities or other changes among facilities) that are intended to address matters other than Specifications or the process used to manufacture or supply Bulk Product or Finished US Goods
but which may have an effect on the same; and (ii) changes to Specifications or the process used to manufacture or supply Bulk Product or Finished US Goods, for batches of Bulk Product or Finished US Goods resulting from a particular production
campaign, due to events or circumstances that arise following the start of such production campaign and are, for Manufacturer, reasonably unexpected with respect to such production campaign. 
 (c) Neither party shall have any obligation to give effect to any Proposed Change that is not a Manufacturer Broader Change unless the
parties agree in writing to effect the Proposed Change (which agreement, except as otherwise set forth herein, shall not be unreasonably withheld or delayed); provided, however, that if such effectiveness is reasonably practicable
before the implementation of such Manufacturer Broader Change, then Manufacturer shall not implement any Manufacturer Broader Change until the effectiveness of any necessary modification to the Regulatory Applications/Approvals for the Product.

  

 18 

 CONFIDENTIAL TREATMENT 
 (d) Manufacturer shall be entitled to implement, and Buyer shall have an obligation to give effect to, Manufacturer Broader Changes on
reasonable advance notice to Buyer and subject to Manufacturer providing, at no cost to Buyer, all reasonable assistance to Buyer to make any regulatory filings required in relation to implementation of any Manufacturer Broader Change within any
applicable time periods required by law; provided, however, that if such effectiveness is reasonably practicable before the implementation of such Manufacturer Broader Change, then Manufacturer shall not implement any Manufacturer
Broader Change until the effectiveness of any necessary modification to the Regulatory Applications/Approvals for the Product. 
 (e) The Proposing Party shall reimburse the Recipient for the reasonable out-of-pocket expenses incurred by the Recipient as a result of any Proposed Change that is implemented. In addition, a party may condition its consent to any Proposed
Change that is not a Manufacturer Broader Change on the implementation of satisfactory reimbursement arrangements to cover its costs and expenses which are beyond reasonable out-of-pocket expenses. 
 (f) Without limiting the calculation of the Manufacturing Cost for any Finished US Goods at issue, Manufacturer may increase the pricing
for Finished US Goods under this Agreement to reflect the Incremental Cost of any Proposed Change made at the request of Buyer. 
 (g) Buyer shall prepare for submission, and Manufacturer shall review and provide comments upon, any regulatory filings relating to the Regulatory Applications/Approvals for the Product required in relation to implementation of any Proposed
Change. For the avoidance of doubt, Manufacturer shall prepare for submission, and Buyer shall review and provide comments upon, any regulatory filings relating to the basic operation of its manufacturing facilities. 
 (h) Manufacturer shall use commercially reasonable efforts to implement any Proposed Changes in a manner that is orderly and avoids any
supply interruption to Buyer. 
 Section 7.6 Complaints; Recalls. 
 (a) Complaints. Buyer shall be solely responsible for handling and investigating all complaints associated with Product in the
United States. Buyer shall promptly notify Manufacturer of all complaints concerning Finished US Goods sold to Buyer pursuant to this Agreement, and Manufacturer shall investigate all such complaints related to the manufacture of Finished US Goods
by Manufacturer and provide a written report to Buyer. 
 (b) Recalls. In the event Manufacturer is required to
initiate a recall, withdrawal or field correction with respect to any Finished US Goods provided under this Agreement, Manufacturer shall immediately notify Buyer in writing. In the event that Buyer believes that a recall, withdrawal or field
correction is necessary with respect to any Finished US Goods provided under this Agreement, Buyer shall so notify Manufacturer and both parties shall cooperate to determine the appropriate action to take. In the event any Governmental Entity issues
a request, directive or order requiring that any Finished US Goods provided under this 

  

 19 

 CONFIDENTIAL TREATMENT 
 Agreement be recalled, or detains or destroys or prevents the release of any Finished US Goods provided under this Agreement, each party shall give the other party telephonic notice (to be confirmed in writing) within
twenty-four (24) hours of the occurrence of such event. In the event of such a recall, withdrawal or field correction, Buyer shall have the sole responsibility to implement the recall or other corrective action, but shall keep Manufacturer
informed on a regular basis of its progress in planning and implementing the recall or other corrective action. Manufacturer shall cooperate with Buyer in connection with, and the provisions of Section 7.6(c) shall be applicable to, any
such action. Without limiting the provisions of Section 5.8, if there is a disagreement between the parties as to whether a recall, withdrawal or field correction is required or advisable, the parties shall in good faith cooperate and
consider each other’s view to reach agreement as promptly as possible on a mutually acceptable course of action in accordance with relevant Governmental Rules. If relevant, either party may refer the matter for analysis to a specialized
laboratory of national reputation acceptable to both parties, and any determination by such laboratory shall be final and binding upon the parties. 
 (c) Cost of Recall. In the event that any Finished US Goods are quarantined or recalled, or are subject to stop-sale or other corrective action, whether voluntary or by Governmental Entity action, then any
expenses (including reasonable fees of any experts or attorneys that may be utilized by either party and Governmental Entity fines or penalties related to such recall, quarantine or stop-sale or other corrective action) shall be borne by Buyer,
except to the extent such quarantine, recall, stop-sale order or other corrective action is demonstrated to be due to failure of Finished US Goods to be manufactured by Manufacturer hereunder in accordance with applicable cGMP Requirements and
Specifications, in which case the expenses (including reasonable fees of any experts or attorneys that may be utilized by either party and Governmental Entity fines or penalties related to such recall, quarantine, stop-sale or other corrective
action) shall be borne by Manufacturer. 
 Section 7.7 Insurance. At all times from the Effective Date through that date which is
five (5) years after the expiration date for the Finished US Goods supplied to Buyer hereunder, Buyer and Manufacturer shall each maintain (or, in the instance of Manufacturer, self-insure for) product liability insurance in an amount of not
less than Fifteen Million Dollars ($15,000,000) annual aggregate, including retention. Each party shall provide the other party with a certificate of insurance on the Effective Date as evidence of such insurance and annually thereafter evidencing
the renewal of such insurance. Each party shall promptly notify the other party of any change in the terms of such insurance from those set forth in the most recent certificate of insurance provided to the other party pursuant to this
Section 7.7. 
 Section 7.8 Manufacturing Transfer. 
 (a) No later than the date which is thirty-six (36) months prior to the end of the Term (or, if applicable, promptly upon a Mid-Term
Transfer Election): (i) Manufacturer shall provide one (1) copy of the Manufacturing Documentation to Buyer; and (ii) Buyer shall submit to Manufacturer a project plan regarding the transfer of the manufacture of Bulk Product and
supply of Finished US Goods for Buyer’s requirements from Manufacturer to Buyer (or a third party manufacturer designated by Buyer). Appropriate representatives of Manufacturer shall meet with appropriate representatives of Buyer within thirty
(30) days after Buyer submits such project plan to Manufacturer to discuss and comment on such project plan. The parties 

  

 20 

 CONFIDENTIAL TREATMENT 
 acknowledge and agree that the goal of the project plan shall be to enable Buyer to effect a transfer of the manufacture of Bulk Product and supply of Finished US Goods for Buyer’s requirements from Manufacturer
and its subcontractors to Buyer or to Buyer’s designee(s) so that Buyer (and/or Buyer’s designee(s)) could commence the manufacture of Bulk Product and the supply of Finished US Goods no later than the end of the Term (or, if applicable,
thirty-six (36) months after a Mid-Term Transfer Election). To that end, the project plan shall include Manufacturer’s agreement to provide, and to use commercially reasonable efforts to cause its subcontractors to provide, Buyer with
(x) access to the facilities of Manufacturer and its subcontractors and (y) access to the personnel of Manufacturer and its subcontractors, in any case limited to those facilities or personnel directly responsible for the manufacture of
Bulk Product and the supply of Finished US Goods. The project plan shall include a detailed timeline for the activities contemplated thereunder as well as a budget. Once the project plan has been agreed to by both Manufacturer and Buyer (which in
any event shall occur no later than thirty (30) months prior to the end of the Term or, if applicable, six (6) months after a Mid-Term Transfer Election), Manufacturer and Buyer shall work diligently to complete the transfer of the Product
Manufacturing Technology and Buyer shall work diligently to obtain Governmental Entity approval for the manufacture of Bulk Product and the supply of Finished US Goods by Buyer or its designee(s) as contemplated by such project plan;
provided, however, that Manufacturer’s obligation in this regard shall (A) be limited to activities that are substantially completed within the specified thirty-six (36)-month period, (B) include no assurance of
success whatsoever and (C) be dependent upon the reasonable competence of Buyer and/or Buyer’s designee(s) with respect to the activities at issue (including obtaining the required approvals in a timely manner for the conduct of
manufacturing activities at a facility selected and prepared by Buyer and/or Buyer’s designee(s) and possession by Buyer and/or Buyer’s designee(s) of the requisite skills, equipment, ingredients and resources for the manufacture of Bulk
Product and Finished US Goods). Notwithstanding any provision herein to the contrary, Manufacturer shall be obligated to participate in the manufacturing transfer activities contemplated by this Section 7.8 only once (i.e., a
Mid-Term Transfer Election will render void any obligation of Manufacturer in this regard that would otherwise exist during the last thirty-six (36) months of the Term). 
 (b) Except as provided in Section 7.8(f), in respect of the performance by Manufacturer of the activities contemplated by this
Section 7.8, Buyer shall, promptly following Manufacturer’s delivery to Buyer from time to time of itemized invoices for the same: (i) reimburse Manufacturer and its subcontractors for (x) all third party costs or expenses
reasonably incurred by Manufacturer or its subcontractors with respect to such activities and (y) the actual costs of all supplies reasonably provided by Manufacturer or its subcontractors with respect to such activities; and (ii) pay
Manufacturer and its subcontractors for time reasonably spent by their personnel on such activities at the FTE Rate. 
 (c)
Effective as of the date of commencement of manufacturing transfer contemplated by this Section 7.8, and without the requirement for the payment of additional consideration by Buyer, Manufacturer hereby grants to Buyer a paid-up,
worldwide, non-exclusive license under Product Manufacturing Technology solely to implement such manufacturing transfer. 
  

 21 

 CONFIDENTIAL TREATMENT 
 (d) Effective as of the date of the completion of the manufacturing transfer contemplated by this Section 7.8, and without a
requirement for the payment of additional consideration by Buyer, Manufacturer hereby grants to Buyer a paid-up, worldwide, sub-licensable, non-exclusive license under Product Manufacturing Technology solely to make, have made, use, and import Bulk
Product, Finished US Goods and Product for the purpose of offering to sell and selling Product to, or for use by, end-users in the United States. Without limiting the foregoing, Buyer acknowledges and agrees that Manufacturer will continue to
possess rights to the Product Manufacturing Technology (including the right to manufacture the Product for sale to, or use by, end-users outside of the United States). 
 (e) Buyer hereby agrees that it shall use commercially reasonable efforts to effect a transfer of the manufacture of Bulk Product and the
supply of Finished US Goods for Buyer’s requirements from Manufacturer and its subcontractors to Buyer and/or to Buyer’s designees (in either instance, the “Replacement Source”) pursuant to the project plan prior to the
end of the Term (or, if applicable, thirty-six (36) months after a Mid-Term Transfer Election). Upon the grant of FDA approval to any such Replacement Source (the “Replacement Source Approval”), Buyer shall notify Manufacturer
and not submit any further orders under this Agreement, irrespective of whether such Replacement Source thereafter ceases to be authorized to manufacture and supply Bulk Product or Finished US Goods; provided, however, that
(i) unless Manufacturer shall consent to a termination or reduction (in Manufacturer’s sole discretion), Buyer shall remain (x) obligated to deliver Forecasts through the end of the Term as contemplated by Section 3.1 and
(y) committed to the amount of Packages that Buyer is required to order in respect of any such Forecasts (pursuant to Section 3.1) and (ii) in the event of a Mid-Term Transfer Election, Buyer may continue to submit orders
according to Forecasts (as contemplated by Section 3.1) following an ensuing Replacement Source Approval so long as Buyer (x) notifies Manufacturer in writing, as part of its Mid-Term Transfer Election, of Buyer’s intention to
do so and (y) purchases from Manufacturer pursuant to this Agreement at least seventy percent (70%), measured on a rolling twelve (12)-month basis, of Buyer’s requirements for Finished US Goods (as well, if applicable, as any other form of
Product or portion thereof) during the portion of the Term following such Replacement Source Approval. 
 (f) In the event
Buyer terminates this Agreement due to the uncured breach of this Agreement by Manufacturer (pursuant to Section 8.2(a)(ii)) or pursuant to Article IX, any notice of termination delivered by Buyer may contain Buyer’s election
to commence transfer of manufacturing pursuant to this Section 7.8. If Buyer’s notice of termination includes such an election, the effective date of termination shall not be until the completion of activities under this
Section 7.8 or such earlier date as may be specified in Buyer’s notice of termination. Further, if Buyer terminates this Agreement due to the uncured breach of this Agreement by Manufacturer, the provisions of clause
(ii) of Section 7.8(b) (i.e., with respect to Buyer paying Manufacturer and its subcontractors for time reasonably spent by their personnel at the FTE Rate) shall not apply. 
 Section 7.9 Manufacturing Supply Team; Bulk Product Reports. 
 (a) Manufacturer and Buyer shall, as soon as practicable following the Effective Date, form a manufacturing supply team (the
“Manufacturing Supply Team”) of two (2) people, one to be designated by Manufacturer and one to be designated by Buyer. The 

  

 22 

 CONFIDENTIAL TREATMENT 
 Manufacturing Supply Team shall meet on a periodic basis during the Term and shall address any issues related to the manufacture and supply of Bulk
Product and Finished US Goods under this Agreement; provided, however, that in the event Manufacturer is more than sixty (60) days late on the delivery for any order and Buyer’s inventory of Finished US Goods is less than or
equal to three (3) months’ of supply, the Manufacturing Supply Team shall meet not less than once per month (until such order is delivered) to address any issues or difficulties that Manufacturer may be experiencing related to the supply
of Finished US Goods. The meetings of the Manufacturing Supply Team may be conducted by telephone. 
 (b) From time to time
during the Term (but no more frequently than once every six (6) months), Manufacturer will, upon Buyer’s request, provide Buyer with then current information regarding the amount, and the time remaining until the expiry date, of
Manufacturer’s inventories of (i) Bulk Product and (ii) the unconjugated antibody (Ibritumomab) used to make Bulk Product. 
 Section 7.10 Manufacturer NDC Numbers. Until the earlier of (i) December 31, 2007 or (ii) Buyer’s establishment of the Buyer NDC Number as set forth in Section 7.11, Manufacturer shall not
discontinue the NDC Number. 
 Section 7.11 Buyer NDC Number. Buyer shall establish a new NDC Number (the “Buyer NDC
Number”) no later than December 31, 2007 and notify Manufacturer thereof. Buyer agrees that, within five (5) days following the Effective Date, it shall apply for, and initiate applicable processes to obtain, the Buyer NDC Number.
Buyer shall be permitted to continue to sell any Finished US Goods inventory with the NDC Number that may be provided to Buyer pursuant to the arrangements contemplated hereby until such inventory is exhausted; provided, however, that
Buyer shall sell all Finished US Goods bearing the NDC Number prior to selling any products or inventory bearing the Buyer NDC Number. 
 ARTICLE VIII 
 TERM AND TERMINATION 
 Section 8.1 Term. This Agreement shall commence on the Effective Date and shall expire on June 9, 2014, unless earlier terminated in accordance with this Article VIII (the
“Term”). 
 Section 8.2 Termination. 
 (a) Manufacturer and Buyer shall each have the right to terminate this Agreement with immediate effect upon written notice to the other
upon the occurrence of any of the following: 
 (i) The other party files a petition in bankruptcy, or enters into an
agreement with its creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law.

  

 23 

 CONFIDENTIAL TREATMENT 
 (ii) The other party fails to cure any material noncompliance with any of the terms and conditions hereof or of the Quality Agreement
within the time period specified in any written notice delivered to such non-compliant party, which shall be at least thirty (30) days; provided, however, that (i) such period, for any matter other than a payment, shall be
extended for so long as the party at issue has commenced efforts to cure the breach and is attempting, in good faith, to complete such efforts (subject to a maximum aggregate period of one hundred eighty (180) days), (ii) such period, with
respect to any payment, may be as little as ten (10) days and (iii) the provisions of this Section 8.2(a)(ii) shall not be construed as modifying the provisions of Section 3.2(a). 
 (b) Manufacturer shall have the additional right to terminate this Agreement with immediate effect upon written notice to Buyer upon Buyer
failing to cure any material noncompliance with any of the terms and conditions of any of the Transaction Documents (other than this Agreement) within the time period specified in any written notice (which shall be at least sixty (60) days)
delivered to Buyer; provided, however, that the foregoing shall not apply to any such non-compliance relating solely to a good faith payment dispute so long as such dispute remains unsettled and any amounts not in dispute have been
timely paid. 
 Section 8.3 Effect of Termination If this Agreement is terminated pursuant to Section 8.2:

 (a) Buyer acknowledges and agrees that Manufacturer shall be entitled to cancel any order under this Agreement accepted
prior to the date notice of termination is given, and shall not be obligated to ship any Finished US Goods ordered by Buyer pursuant to any such order except as such Finished US Goods may be included in shipments pursuant to Section 8.4.

 (b) The termination of this Agreement shall not release Buyer from the obligation to pay any sum that may be owing to
Manufacturer (whether then or thereafter due to Manufacturer and including, for this purpose, any expenses incurred in manufacturing Bulk Product or supplying Finished US Goods in respect of Buyer’s minimum requirements under the then most
recently delivered Forecast or in respect of commitments made by Manufacturer or its subcontractors in anticipation thereof) or operate to discharge any liability under this Agreement that had accrued prior to any such termination. 
 (c) During the period between the giving of any notice of termination pursuant to this Article VIII and the effective date of the
termination as set forth in such notice, all Finished US Goods shall be provided to Buyer solely on a C.O.D. basis. 
 Section 8.4
Termination or Expiration of Agreement. 
 (a) Upon the termination or expiration of this Agreement, Manufacturer shall
transfer, or shall cause to be transferred, all Finished US Goods that have been manufactured in anticipation of delivery to Buyer under this Agreement, as well as all work in process relating to such Finished US Goods that are then in
Manufacturer’s possession (including Bulk Product), to fulfill Manufacturer’s obligations hereunder, but only to fulfill Manufacturer’s obligations hereunder, by delivery to Buyer at the price determined in accordance with this
Agreement (or a proportionate price based upon the extent of completion); provided, however, that in the instance 

  

 24 

 CONFIDENTIAL TREATMENT 
 of a termination by Manufacturer for Buyer’s uncured material noncompliance pursuant to Section 8.2(a)(ii) or
Section 8.2(b), such transfer shall be at the election of Manufacturer. Buyer shall pay for all such Finished US Goods and work in process relating to such Finished US Goods on a C.O.D. basis. 
 (b) It is understood and agreed that Buyer shall be responsible for the manufacture and supply of Bulk Product and Finished US Goods for
Buyer’s requirements after the earlier of the termination or expiration of this Agreement. In addition, it is understood and agreed that Buyer shall be responsible, at its sole expense, for the validation and qualification, including analytic
method testing, of any new manufacturing facility to be used by Buyer. 
 (c) Termination or expiration of this Agreement
shall not relieve the parties of any obligation accruing prior to such termination. Without limiting the foregoing, the rights and obligations of the parties under Sections 4.3, 5.8, 7.6, 7.7, 8.3 and 8.4
and Articles VI, X, XI and XIII of this Agreement shall survive any expiration or termination of this Agreement. 
 ARTICLE IX 
 FORCE_MAJEURE 
 Notwithstanding any provision of this Agreement to the contrary, neither party shall be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term or provision
of this Agreement (other than the payment of money) when such failure or delay is caused by any of the following and not by the party seeking protection under this provision: fire; flood; accident; explosion; equipment or machinery breakdown not
related to Manufacturer’s negligence in preventive maintenance; sabotage; strike or any labor disturbance (regardless of the reasonableness of the demands of labor); civil commotions; riots; invasions; wars (present or future); acts,
restraints, requisitions, regulations or directions of any Governmental Entity; voluntary or mandatory compliance by Manufacturer with any request of any Governmental Entity; voluntary or mandatory compliance by Manufacturer with any request for
material represented to be for purposes of (directly or indirectly) producing articles for national defense or national defense facilities; shortage of labor, fuel, power or raw materials; inability to obtain supplies; failures of normal sources of
supplies; inability to obtain or delays of transportation facilities; any act of God; any act or omission of Buyer (insofar as Manufacturer or the transactions or arrangements contemplated by this Agreement are concerned); or any cause (whether
similar or dissimilar to the foregoing) beyond the reasonable control of a party or Manufacturer’s normal sources of supply of any products affecting the production or delivery of Finished US Goods. If any such disability delays any shipment
hereunder for more than one-hundred eighty (180) days, such shipment may be canceled at Manufacturer’s option or Buyer may terminate this Agreement. 
  

 25 

 CONFIDENTIAL TREATMENT 
 ARTICLE X 
 CONFIDENTIALITY AND RESTRICTED USE 
 Section 10.1 Nondisclosure and Restricted Use Obligations. 
 (a) Confidential Information. Each party (a “Receiving Party”) acknowledges that it may receive (or, as the result
of one or more transfers contemplated hereby or by the Asset Purchase Agreement or any other Transaction Document, it may be or become in possession of) Confidential Information of another party (a “Disclosing Party”) in the
performance of this Agreement or any other Transaction Document. Each Receiving Party shall use commercially reasonable efforts to safeguard and to hold the Confidential Information of a Disclosing Party in confidence, and shall limit disclosure of
such Confidential Information to those employees and consultants of the Receiving Party and its Affiliates who are bound by obligations of confidentiality to the Receiving Party consistent with the terms of this Article X. A Receiving Party
shall not, directly or indirectly, disclose, publish or use for the benefit of any other Person or itself, except in performing this Agreement or any other Transaction Document, any Confidential Information of a Disclosing Party without first having
obtained the Disclosing Party’s written consent to such disclosure or use. The foregoing shall not be construed to prevent the necessary disclosure of Confidential Information to a Governmental Entity by a party in the exercise of its rights
under this Agreement or any other Transaction Document, provided that such party exercises commercially reasonable efforts to limit the extent of such disclosure as well as any further disclosure by such Governmental Entity. 
 (b) Manufacturing Confidential Information. To the extent that any Confidential Information constitutes Manufacturing Confidential
Information, then in addition to Buyer’s obligations under the foregoing subsection (a), Buyer shall: (i) safeguard and hold such Manufacturing Confidential Information in strict confidence; (ii) not use such Manufacturing
Confidential Information other than in the manufacture or supply of the Product solely for the purpose of offering to sell and selling Product to, or for use by, end-users in the United States; and (iii) limit disclosure of such Manufacturing
Confidential Information only to third party manufacturers and contractors engaged by Buyer which are bound by obligations of confidentiality and restricted use (i.e., requiring such third party manufacturers and contractors to (x) not
use such Manufacturing Confidential Information other than in the manufacture or supply of the Product solely for sale to or use by end-users in the United States and (y) not further disclose such Manufacturing Confidential Information to any
Person under any circumstances). 
 Section 10.2 Exception for Legal Requirement. A Receiving Party shall be entitled to disclose
any Confidential Information of a Disclosing Party: (i) if, in the opinion of the Receiving Party’s outside counsel or general counsel, such public announcement or public statement is necessary to avoid committing a violation of any
Governmental Rule or any regulation of any securities association, stock exchange or national securities quotation system on which the Receiving Party’s securities are, or are proposed to be, listed or traded, or by order of any Governmental
Entity: (ii) as may be necessary or appropriate in connection with the enforcement of this Agreement or any other Transaction Document; or (iii) as may be required in furtherance of a party’s obligations under this Agreement or any
other Transaction Document; provided, however, that in any such event, the Receiving Party shall give advance written notice to the Disclosing Party and use commercially reasonable efforts, wherever possible, to obtain confidential
treatment of such information by the applicable Governmental Entity or other recipient (and, in the case of clause (i), the Disclosing Party shall be provided with a copy of the proposed disclosure in sufficient time to allow a reasonable
opportunity to comment thereon) to the extent practicable. 
  

 26 

 CONFIDENTIAL TREATMENT 
 Section 10.3 Extended Term of Confidentiality Obligations. The obligations set forth in this Article X shall survive the termination
or expiration of this Agreement for five (5) years. Nothing in this Article X shall be construed to create or imply any right or license under any patent, trademark, copyright or other intellectual property right owned or controlled by a
party or its Affiliates (except as may be expressly set forth elsewhere in this Agreement or any other Transaction Document). 
 Section 10.4 Injunctive Relief. In addition to any other relief or remedy available to it at law or in equity, each party shall be entitled to seek temporary or permanent injunctive relief from any court of competent
jurisdiction, without the posting of any bond, in order to enforce its rights as to the other party’s performance of its covenants under this Article X. 
 Section 10.5 Supplement to Confidentiality Agreement. The obligations of this Article X shall supplement (i.e., be in addition to), but not supersede, the Confidentiality Agreement or any
confidentiality provisions in any other Transaction Document (including the Asset Purchase Agreement). 
 ARTICLE XI 
 INDEMNIFICATION 
 Section 11.1
By Manufacturer. Manufacturer shall indemnify, defend and hold harmless the Buyer Indemnified Parties (and, as applicable, any contractors of Buyer) from and against any and all Losses resulting from claims of third parties (i.e.,
parties other than the parties hereto and their Affiliates and, as applicable, any contractors of Buyer) to the extent such Losses arise out of or result from a failure of Finished US Goods to be manufactured by Manufacturer or its Affiliates,
subcontractors or assignees hereunder in accordance with applicable cGMP Requirements and the Specifications; provided, however, that Manufacturer shall not be so obligated (i) with respect to any failure of Finished US Goods to
be manufactured in accordance with applicable cGMP Requirements and the Specifications where such Finished US Goods were not rejected by Buyer and the same is known, or reasonably should have been known, to Buyer or any of its Affiliates,
contractors or assignees or (ii) to the extent any such Losses result from (x) any act or omission of Buyer or any of its Affiliates, contractors or assignees constituting negligence, recklessness or willful misconduct or (y) any
breach of this Agreement by Buyer or any of its Affiliates, contractors or assignees. 
 Section 11.2 By Buyer. Buyer shall
indemnify, defend and hold harmless Manufacturer and the other Seller Indemnified Parties (and, as applicable, any subcontractors or assignees of Manufacturer) from and against any and all Losses resulting from claims of third parties (i.e.,
parties other than the parties hereto and their Affiliates) to the extent such Losses arise out of or result from the manufacture, promotion, sale, distribution or use of any Bulk Product, Finished US Goods or Product by or on behalf of (or through)
any Buyer Indemnified Party or any contractor, successor or assignee thereof following the Effective Date; provided, however, that Buyer’s obligations under this Section 11.2 shall not extend to any Losses suffered by
Manufacturer or any of the other Seller Indemnified Parties (and subcontractors or assignees of Manufacturer) as to which Manufacturer has agreed to indemnify Buyer pursuant to Section 11.1. 
  

 27 

 CONFIDENTIAL TREATMENT 
 Section 11.3 Procedures. In the event of any claims for indemnification made by one party (or, in the instance of Buyer or Manufacturer, any
other Buyer Indemnified Party or Seller Indemnified Party, respectively, or its contractors/subcontractors or assignees, as applicable) against the other party under this Article XI, the procedure to be used for the administration and
resolution of such claims shall be as set forth in Section 12.6 of the Asset Purchase Agreement. The amount of any Losses for which indemnification is provided under this Article XI shall be net of any amounts recovered or
recoverable by the indemnified party under insurance policies with respect to such Losses. 
 Section 11.4 Exclusive Remedy.
Buyer acknowledges and agrees that the indemnification provided in this Article XI shall be the sole and exclusive remedy against Manufacturer and its Affiliates, subcontractors and assignees for the Buyer Indemnified Parties (and, as
applicable, any contractors or assignees of Buyer) from and against any and all Losses arising from claims of third parties and, in furtherance thereof, Buyer waives, from and after the Effective Date with respect to Losses arising from claims of
third parties, to the fullest extent permitted under applicable law, any and all rights, claims, actions or causes of action (other than claims of, or causes of action arising from, fraud) it (or any of the other Buyer Indemnified Parties or any
contractors or assignees of Buyer) may have against Manufacturer or any of its Affiliates, subcontractors or assignees in respect of such third party claims relating to or arising at law, under any statute, in equity or otherwise out of this
Agreement or the transactions contemplated hereby, other than the remedies provided in this Article XI; provided, however, Buyer shall be entitled to seek temporary or permanent injunctive relief or specific enforcement in order
to enforce its rights under this Agreement. 
 ARTICLE XII 
 INTELLECTUAL PROPERTY RIGHTS 
 Buyer hereby grants to Manufacturer and to each third party or
subcontractor that Manufacturer may use or designate to manufacture Bulk Product or to supply Buyer’s requirements of Finished US Goods, for the Term, a royalty-free, nontransferable, non-exclusive right and license (with the right to
sublicense) under the Product Intellectual Property to manufacture Bulk Product and to supply Finished US Goods as contemplated hereby. 
  

 28 

 CONFIDENTIAL TREATMENT 
 ARTICLE XIII 
 MISCELLANEOUS 
 Section 13.1 LIMITATION ON LIABILITY. NONE OF MANUFACTURER, BUYER NOR THEIR RESPECTIVE AFFILIATES OR CONTRACTORS/SUBCONTRACTORS SHALL BE
LIABLE FOR PUNITIVE, EXEMPLARY, SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF OR RELATING TO THIS AGREEMENT; PROVIDED, HOWEVER,
THAT THIS EXCLUSION IS NOT INTENDED TO, NOR SHALL, EXCLUDE ACTUAL OR COMPENSATORY DAMAGES OF THE AFFECTED PARTY, WHICH ACTUAL OR COMPENSATORY DAMAGES INCLUDE INDEMNIFICATION UNDER ARTICLE XI FOR AMOUNTS A PARTY IS REQUIRED TO PAY A THIRD
PARTY. 
 Section 13.2 Assignment. Neither Manufacturer nor Buyer may assign its rights or obligations under this Agreement
without the prior written consent of the other party; provided, however, that (i) Manufacturer may subcontract its obligations under this Agreement and, (ii) so long as any such successor or assign agrees in writing to be
bound by this Agreement, either party may assign its rights and obligations under this Agreement, without the prior written consent of the other party, to an Affiliate or to a successor of the relevant portion of the assigning party’s business
by reason of merger, sale of all or substantially all of its assets or securities or any similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve either party of its
responsibility for the performance of any obligation under this Agreement. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns. 
 Section 13.3 Severability. If any term or other provision of this Agreement is held to be illegal, invalid or unenforceable by any
Governmental Rule or public policy, all other terms or provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner
materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. 
  

 29 

 CONFIDENTIAL TREATMENT 
 Section 13.4 Notices. All notices, requests and other communications hereunder shall be in writing and shall be sent, delivered or mailed,
addressed as follows: 
  

	 	(a)	if to Buyer: 

 Cell Therapeutics, Inc. 
 501 Elliott Avenue, Suite 400 
 Seattle, WA
98119 
 Telephone: (206) 282-7100 
 Facsimile: (206) 284-6114 
 Attn: Legal Affairs 
 with a copy to: 
 Heller Ehrman LLP 
 4350 La Jolla Village Drive, 7th Floor 
 San
Diego, CA 92122 
 Telephone: (858) 450-8400 
 Facsimile: (858) 450-8499 
 Attn: Richard A. Kaufman, Esq. 
  

	 	(b)	if to Manufacturer: 

 Biogen Idec Inc. 
 5200 Research Place 
 San Diego, CA 92122

 Telephone: (858) 401-5747 
 Facsimile: (858) 795-9117 
 Attn: Rolf Schild 
 with a copy to: 
 Pillsbury Winthrop Shaw Pittman LLP 
 12255 El Camino Real, Suite 300 
 San Diego,
California 92130 
 Telephone: (858) 509-4000 
 Facsimile: (858) 509-4010 
 Attn: Mike Hird 
 Each such notice, request or other communication shall be given by: (i) hand delivery; (ii) by certified mail; or (iii) nationally recognized courier
service. Each such notice, request or communication shall be effective when delivered at the address specified in this Section 13.4 (or in accordance with the latest unrevoked direction from the receiving party). It is understood and
agreed that this Section 13.4 is not intended to govern the ordinary course business communications necessary between the parties in performing their duties, in due course, under the terms of this Agreement, including the placement of
orders and the delivery of forecasts. 
 Section 13.5 Applicable Law. This Agreement will be deemed to have been made in the
State of California and its form, execution, validity, construction and effect will be determined in accordance with the laws of the State of California, without giving effect to the principles of conflicts of law thereof. 
  

 30 

 CONFIDENTIAL TREATMENT 
 Section 13.6 Entire Agreement. This Agreement and the attached Schedules and Exhibits, which are incorporated herein, together with the
Quality Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and all prior agreements with respect hereto are superseded; provided, however, that to the extent of any conflict or
inconsistency between the provisions of the Quality Agreement and this Agreement, the provisions of this Agreement shall control. Each party confirms that it is not relying on any representations, warranties, covenants or understandings of any kind,
nature or description whatsoever of the other party, except such as are as specifically set forth herein, except that nothing herein shall be construed as intended to relieve or release Buyer from its obligation to make payment of monies or satisfy
any other obligations which Buyer may owe to Manufacturer. No amendment or modifications hereof shall be binding upon the parties unless set forth in a writing specified to be an explicit amendment to this Agreement duly executed by authorized
representatives of each party. The parties recognize that, during the Term, purchase orders, acknowledgements or similar routine forms may be used to implement or administer provisions of this Agreement. Therefore, the parties agree that the terms
of this Agreement shall prevail in the event of any conflict between this Agreement and any provision of such forms that add to, vary, modify or are at conflict with the provisions of this Agreement. 
 Section 13.7 Headings. The headings used in this Agreement are intended for convenience only and shall not be considered part of the written
understanding among the parties and shall not affect the construction of this Agreement. 
 Section 13.8 Independent Contractors.
It is expressly agreed that Manufacturer and Buyer shall be independent contractors and that neither the relationship among the parties nor this Agreement shall be construed as creating a partnership, joint venture or agency. Neither Manufacturer
nor Buyer shall have the authority to make any statements, representations or commitments of any kind, or to take any action or to incur any liability or obligation which shall be binding on the other, without the prior consent of the other party to
do so. All persons employed by a party shall be employees of such party and not of the other party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such party. 
 Section 13.9 Waiver. The waiver by either party of any right hereunder or the failure to perform or of a breach by the other party shall not
be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar nature or otherwise. 
 Section 13.10 Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by
each party and delivered by each party to the other party, it being understood that all parties need not sign the same counterpart. 
  

 31 

 CONFIDENTIAL TREATMENT 
 Section 13.11 WAIVER OF JURY TRIAL. EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING
RELATING TO THIS AGREEMENT, THE AGREEMENTS, INSTRUMENTS AND DOCUMENTS CONTEMPLATED HEREBY OR THE TRANSACTIONS CONTEMPLATED HEREBY AND FOR ANY COUNTERCLAIM THEREIN. 
 Section 13.12 No Benefit to Third Parties. The representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of the parties and their successors and permitted
assigns, and, except for the third parties expressly referenced in Article XI (and then solely with respect to the indemnification benefits set forth in such Article XI), nothing herein, express or implied, is intended to or shall
confer upon any other person or entity any legal or equitable rights, benefits or remedies. 
 [SIGNATURE PAGE FOLLOWS] 
  

 32 

 CONFIDENTIAL TREATMENT 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed by their respective representatives thereunto duly authorized, all as of the
Effective Date. 
  

			
	BIOGEN IDEC INC.
		
	By:	 	/s/ Faheem Hasnain
		 	Name:
		 	Title:
	
	CELL THERAPEUTICS, INC.
		
	By:	 	/s/ James Bianco
		 	Name:
		 	Title:

  

 33Securities Purchase Agreement between BNC Bancorp and Synovus Financial Corp.

 Exhibit 10.1 
 SECURITIES PURCHASE AGREEMENT 
 SECURITIES PURCHASE AGREEMENT (this
“Agreement”), dated as of December 31, 2007, by and between BNC Bancorp, a North Carolina corporation with headquarters located at 1226 Eastchester Drive, High Point, North Carolina (the “Company”), and Synovus
Financial Corp., a Georgia corporation (“Synovus”). 
 BACKGROUND 
 A. The Company and Synovus are executing and delivering this Agreement in reliance upon the exemption from registration afforded by Section 4(2) of
the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the Securities Act. 
 B. Synovus wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this
Agreement, 355,544 shares of the common stock, no par value per share (“Common Stock”), of the Company (the “Securities”) at a purchase price per share of $15.75 (the “Purchase Price”). 

NOW, THEREFORE, IN CONSIDERATION of the representations, warranties, covenants and agreements contained in this Agreement, and for other good and
valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and Synovus agree as follows: 
 ARTICLE I

 PURCHASE AND SALE 
 1.1
Closing. Subject to the terms and conditions set forth in this Agreement, at the closing of the purchase and sale of the Securities (the “Closing”) the Company shall issue and sell to Synovus, and Synovus shall purchase from
the Company, the Securities at the Purchase Price. The date and time of the Closing shall be 9:00 a.m., Eastern Standard Time, on December 31, 2007 (the “Closing Date”). The Closing shall take place at the offices of Brooks,
Pierce, McLendon, Humphrey & Leonard, L.L.P, 230 North Elm Street, Suite 2000, Greensboro, North Carolina. 
 1.2 Closing
Deliveries. 
 (a) At the Closing, the Company shall deliver or cause to be delivered to Synovus one or more stock certificates in form
and substance satisfactory to Synovus evidencing 355,544 shares of Common Stock, registered in the name of Synovus. 
 (b) At the Closing,
Synovus shall deliver or cause to be delivered to the Company the Purchase Price in United States dollars and in immediately available funds, by wire transfer to an account designated in writing to Synovus by the Company for such purpose.

 ARTICLE II 
 COMPANY REPRESENTATIONS AND WARRANTIES 
 2.1 Organization and Good Standing of the Company;
Organizational Documents. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of North Carolina and has all requisite power and authority to own, operate and lease its properties and to
carry on its business. The Company is duly licensed or qualified as a foreign corporation for the transaction of business and is in good standing under the laws of each jurisdiction in which it owns or leases properties, or conducts business. True,
complete and correct copies of the Company’s articles of incorporation and by-laws, as in effect as of the date of this Agreement, are publicly available on the website of the SEC. 
 2.2 Organization and Good Standing of Subsidiaries. Each Subsidiary of the Company is duly organized, validly existing and in good standing under
the laws of its jurisdiction of organization, and has all requisite power and authority to own, operate and lease its properties and to carry on its business, and is duly licensed or qualified to do business in each other jurisdiction in which it
owns or leases properties, or conducts business. The deposit accounts of the banking Subsidiaries of the Company are insured by the Federal Deposit Insurance Corporation (the “FDIC”) to the fullest extent permitted by the Federal
Deposit Insurance Act and the rules and regulations of the FDIC thereunder, and all premiums and assessments required to be paid in connection therewith have been paid when due. For purposes of this Agreement, “Subsidiary” means,
with respect to any Person, any other Person of which 50% or more of the shares of the voting securities or other voting interests are owned or controlled, or the ability to select or elect 50% or more of the directors or similar managers is held,
directly or indirectly, by such first Person or one or more of its Subsidiaries, or by such first Person, or by such first Person and one or more of its Subsidiaries, and “Person” means an individual, corporation, association,
partnership, entity, group (as such term is used in Section 13(d)(3) of the Exchange Act of 1934, as amended (the “Exchange Act”)), trust, joint venture, business trust or unincorporated organization, or a government or any
agency or political subdivision thereof. 
 2.3 Authorization; No Conflicts; Governmental Consents. 
 (a) The Company has full corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby,
including the issuance of the Securities (the “Transactions”). The execution, delivery and performance by the Company of this Agreement and the consummation of the Transactions have been duly authorized by the Board of Directors of
the Company. No other proceedings on the part of the Company (including approval of the Company’s stockholders), including under the NASDAQ rules and regulations relating to the continued listing of the Common Stock under the NASDAQ Capital
Market, are necessary to authorize the execution, delivery and performance by the Company of this Agreement and consummation of the Transactions. This Agreement has been duly and validly executed and delivered by the Company. This Agreement is a
valid and binding obligation of the Company enforceable against the Company in accordance with its terms. 
 (b) The execution, delivery and
performance of this Agreement, the consummation by the Company of the Transactions and the compliance by the Company with any of the provisions hereof will not conflict with, violate or result in a breach of any 

  

 2 

 
provision of, or constitute a default (or an event which, with notice or lapse of time or both would constitute a default) under, or give rise to any rights
of any Person other than the parties to this Agreement or give rise to any obligations of the Company other than under this Agreement, or result in the termination of or accelerate the performance required by, or result in a right of termination or
acceleration under (x) any provision of the articles of incorporation or by-laws of the Company or (y) any mortgage, note, indenture, deed of trust, lease, loan agreement, commitment, arrangement, written or oral contract or other
agreement or instrument or any permit, concession, grant, franchise, license, judgment, order, decree, ruling, injunction, statute, law, ordinance, rule or regulation applicable to the Company or any of its properties or assets. 
 (c) No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Entity is required on the part of the
Company or any of its Subsidiaries in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of the Transactions. The Securities have been duly authorized by all necessary
corporate action. No “business combination” “moratorium,” “control share,” “fair price,” “takeover,” “interested stockholder” or other takeover law is applicable to the Transactions. For
purposes of this Agreement, “Governmental Entity” means any court, administrative agency or commission or other governmental authority or instrumentality, whether federal, state, local or foreign, and any applicable industry
self-regulatory organization. 
 2.4 Capitalization; Valid Issuance of Securities. 
 (a) The authorized capital stock of the Company consists of 80,000,000 shares of Common Stock of which 6,909,465 shares are issued and outstanding, and
20,000,000 shares of preferred stock of which no shares are issued and outstanding. The Company holds no shares of Common Stock in its treasury. There are 427,508 shares of Common Stock reserved for issuance in connection with employee benefit,
stock option and dividend reinvestment and stock purchase plans. All of the issued and outstanding shares of the Company’s capital stock have been duly and validly authorized and issued and are fully paid and nonassessable, and are not subject
to preemptive rights. No bonds, debentures, notes or other indebtedness having the right to vote on any matters on which the stockholders of the Company may vote (“Voting Debt”) are issued and outstanding. Other than as set forth in
this Section 2.4(a) or pursuant to this Agreement, (A) no equity securities or Voting Debt of the Company are or may be required to be issued by reason of any options, warrants, rights to subscribe to, calls or commitments of any character
whatsoever, (B) there are outstanding no securities or rights convertible into or exchangeable for any equity securities or Voting Debt of the Company and (C) there are no contracts, commitments, understandings or arrangements by which the
Company is bound to issue additional equity securities or Voting Debt or options, warrants or rights to purchase or acquire any additional equity securities or Voting Debt. The consummation of the Transactions will not result in the triggering of
any anti-dilution adjustment provisions of any security of the Company convertible into equity securities of the Company. The Securities represent 4.9% of the Company’s issued and outstanding shares of Common Stock as of the date of this
Agreement after giving effect to any shares of Common Stock to be issued under this Agreement to Synovus. 
  

 3 

 (b) All of the issued and outstanding shares of capital stock or other equity ownership interests of each
Subsidiary of the Company are owned by the Company, directly or indirectly, free and clear of any material liens, pledges, charges and security interests and similar encumbrances, and all of such shares or equity ownership interests have been duly
and validly authorized and issued and are fully paid and nonassessable, and are not subject to preemptive rights. None of the outstanding shares of capital stock or other securities of any Subsidiary were issued in violation of the Securities Act or
any other applicable federal state or local law, rule or regulation. No Subsidiary of the Company has or is bound by any outstanding subscriptions, options, warrants, calls, commitments or agreements of any character calling for the purchase or
issuance of any shares of capital stock or any other equity security of such Subsidiary or any securities representing the right to purchase or otherwise receive any shares of capital stock or any other equity security of such Subsidiary.

 (c) When issued as contemplated by this Agreement, the Securities (i) will be validly issued, fully paid and non-assessable and free
from all taxes, liens, claims and encumbrances, (ii) will not be subject to preemptive rights, rights of first refusal or other similar rights of stockholders of the Company or any other person and (iii) will not impose personal liability
on the holder thereof. 
 2.5 Reports; Financial Statements; Controls. 
 (a) Except as set forth on Schedule 2.5, since January 1, 2005, the Company and each of its Subsidiaries has timely filed all reports,
registration statements, proxy statements and other materials, together with any amendments required to be made with respect thereto, that were required to be filed with (i) the SEC under the Securities Act or the Exchange Act (the “SEC
Reports”), (ii) the North Carolina Commissioner of Banks, North Carolina Department of Commerce, (iii) the Federal Reserve Board, (iv) the FDIC and (v) any other Governmental Entity (all such reports and statements are
collectively referred to herein as the “Reports”), and have paid all fees and assessments due and payable in connection therewith. As of their respective dates, the Reports complied in all material respects with all of the statutes
and published rules and regulations enforced or promulgated by the regulatory authority with which they were filed and (i) with respect to Reports filed with the SEC, did not as of the date of filing thereof with the SEC contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading and (ii) with respect
to all other Reports, were complete and accurate in all material respects as of their respective dates. There are no facts relating to the Company or any of its Subsidiaries that the Company has not disclosed in the Reports or to Synovus in writing
that, individually or in the aggregate, have had or would reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole. No executive officer of the Company has failed to make the certifications
required of him or her under Section 302 or 906 of the Sarbanes-Oxley Act of 2002. 
 (b) Each of the consolidated balance sheets, and
the related consolidated statements of income, changes in stockholders’ equity and cash flows, included in the Reports filed with the SEC under the Exchange Act (A) have been prepared from, and are in accordance with, the books and records
of the Company and its Subsidiaries, (B) fairly present in all material respects the 

  

 4 

 
consolidated financial position of the Company and its consolidated Subsidiaries as of the dates shown and the results of the consolidated operations,
changes in stockholders’ equity and cash flows of the Company and its consolidated Subsidiaries for the respective fiscal periods or as of the respective dates therein set forth, subject, in the case of any unaudited financial statements, to
normal recurring year-end audit adjustments, (C) complied as to form, as of their respective dates of filing with the SEC, in all material respects with applicable accounting requirements and with the published rules and regulations of the SEC
with respect thereto and (D) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) consistently applied during the periods involved, except as otherwise set
forth in the notes thereto. 
 2.6 Absence of Certain Changes. Since September 30, 2007, and except as publicly disclosed by the
Company in the Reports filed by it with the SEC and publicly available prior to the date hereof, (a) the Company and its Subsidiaries have conducted their respective businesses in all material respects in the ordinary course, consistent with
prior practice, (b) the Company has not made or declared any distribution in cash or in kind to its stockholders or issued or repurchased any shares of its capital stock or other equity interest, and (c) no event or events have occurred
that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole. 
 2.7 No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any liabilities or obligations of any nature (absolute, accrued, contingent or otherwise) that are not fully reflected or
reserved against in the financial statements described in Section 2.5(b), except for liabilities that have arisen since September 30, 2007 in the ordinary and usual course of business and consistent with past practice that would not
reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole. 
 2.8 Compliance with
Law. Each of the Company and its Subsidiaries holds all licenses, franchises, permits and authorizations necessary for the lawful conduct of its business under, and has complied with and is not in default or violation in any respect of, any
applicable law, statute, order, rule, regulation, policy or guideline of any Governmental Entity. 
 2.9 Legal Proceedings. There are
no pending, or to the knowledge of the Company, threatened, legal, administrative, arbitral or other proceedings, claims, actions or governmental investigations against the Company or any of its Subsidiaries or to which any of their assets are
subject that, (i) individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on the Company and its Subsidiaries, taken as a whole, or (ii) relating to or which challenges the validity or
propriety of the Transactions. Neither the Company nor any of its Subsidiaries is subject to any order, judgment or decree of a Governmental Entity that, individually or in the aggregate, has had or would reasonably be expected to have a material
adverse effect on the Company and its Subsidiaries, taken as a whole. 
 2.10 Regulatory Actions. Since January 1, 2005 neither
the Company nor any of its Subsidiaries has received any written communication from any federal or state banking authority (“Banking Authority”) (i) asserting that it is in material violation of any law, (ii) threatening
to revoke any of its material permits or licenses, (iii) requiring it (x) to enter into or consent to the issuance of a cease and desist order, written agreement, consent decree, directive, commitment or memorandum of understanding, or
(y) to adopt 

  

 5 

 
any policy, procedure or resolution of its Board of Directors or similar undertaking, that restricts the conduct of its business, or relates to its capital
adequacy, its credit or reserve policies, it management, or the payment of dividends or any other policy or procedure or (iv) threatening or contemplating revocation or limitation of, or which would have the effect of revoking or limiting, FDIC
deposit insurance, and neither the Company nor any of its Subsidiaries has received any written notice from a Banking Authority that it is considering issuing or requiring any of the foregoing. 
 2.11 Offering of Securities. Neither the Company nor any Person acting on its behalf has offered the Securities or any similar securities of the
Company for sale to, solicited any offers to buy any of the Securities or any similar securities of the Company from or otherwise approached or negotiated with respect to any of the Securities or any similar securities of the Company with any Person
other than Synovus. Neither the Company nor any Person acting on its behalf has taken or will take any action (including any offering of any securities of the Company under circumstances that would require the integration of such offering with the
offering of any of the Securities under the Securities Act and the rules and regulations of the SEC thereunder) that might subject the offering, issuance or sale of any of the Securities to the registration requirements of the Securities Act.

 2.12 Listing; Form S-3 Eligibility. The Common Stock is currently listed for trading on the NASDAQ Capital Market. The Company is
not in violation of the listing requirements of the NASDAQ Capital Market, does not reasonably anticipate that the Common Stock will be delisted by the NASDAQ Capital Market for the foreseeable future, and since January 1, 2005 has not received
any notice regarding the possible delisting of the Common Stock from the NASDAQ Capital Market. The Company is eligible to register the resale of its Common Stock on a registration statement on Form S-3 under the Securities Act. The Company is not
aware of any current facts or circumstances that would prohibit or delay the preparation and filing of a registration statement on Form S-3 (in accordance with the schedule provided in Article IV) with respect to the Registrable Securities (as
defined in Article IV). The Company has no basis to believe that its past or present independent public auditors will withhold their consent to the inclusion, or incorporation by reference, of their audit opinion concerning the Company’s
financial statements that are to be included in the Registration Statement required to be filed pursuant to Article IV. 
 2.13 Brokers
and Finders. Except for Burke Capital Group, LLC (the fees and expenses of which will be paid by the Company), neither the Company nor any of its Subsidiaries nor any of their respective officers, directors, employees or agents has utilized any
broker, finder, placement agent or financial advisor or incurred any liability for any fees or commissions in connection with the Transactions. 
 ARTICLE III 
 OTHER AGREEMENTS OF THE PARTIES 
 3.1 No Public Sale or Distribution. Synovus is acquiring the Securities in the ordinary course of business for its own account and not with a view towards, or for resale in connection with, the public sale or
distribution thereof, except pursuant to sales registered under the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities 

  

 6 

 
laws, and Synovus does not have a present arrangement to effect any distribution of the Securities to or through any person or entity; provided,
however, that by making the representations herein, Synovus does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to
a registration statement or an exemption under the Securities Act. 
 3.2 Investor Status. At the time Synovus was offered the
Securities, it was, and at the date hereof it is, either (A) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act or (B) an “accredited investor” as defined in Rule 501(a)(1),
(2) or (3) under the Securities Act. 
 3.3 Organization and Good Standing of Synovus; Authorization. Synovus is a
corporation duly organized, validly existing and in good standing under the laws of the State of Georgia. Synovus has full corporate power and authority to execute and deliver this Agreement and to consummate the Transactions. The execution,
delivery and performance by Synovus of this Agreement and the consummation of the Transactions have been duly authorized by Synovus. No other proceedings on the part of Synovus are necessary to authorize the execution, delivery and performance by
Synovus of this Agreement and consummation of the Transactions. This Agreement has been duly and validly executed and delivered by Synovus. This Agreement is a valid and binding obligation of Synovus enforceable against Synovus in accordance with
its terms. 
 3.4 Access to Information. Synovus acknowledges that it has reviewed disclosure materials provided by the Company and
has been afforded: (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and
risks of investing in the Securities; (ii) access to information (other than material non-public information) about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to
enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision
with respect to the investment. Synovus acknowledges receipt of copies of the SEC Reports. 
 3.5 Furnishing of Information. So long
as Synovus (or any of its Affiliates) beneficially owns any of the Securities, the Company shall timely file all reports required to be filed with the SEC pursuant to the Exchange Act, and the Company shall not terminate its status as an issuer
required to file reports under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would permit such termination. In addition, the Company shall take all actions necessary to meet the “registrant eligibility”
requirements set forth in the general instructions to Form S-3 or any successor form thereto, to continue to be eligible to register the resale of its Common Stock on a registration statement on Form S-3 under the Securities Act. 
  

 7 

 3.6 Dislosures; Securities Laws; Publicity. 
 (a) The Company shall, on or before 8:30 a.m., Eastern Standard Time, on the first trading day following execution of this Agreement, file a Current
Report on Form 8-K with the SEC (the “8-K Filing”) describing the terms of the Transactions. Thereafter, the Company shall timely file any filings and notices required by the SEC or applicable law with respect to the
Transactions and provide copies thereof to Synovus promptly after filing. 
 (b) The Company shall file with the SEC a Form D with respect to
the Securities as required under Regulation D and provide a copy thereof to Synovus promptly after such filing. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary to qualify the
Securities for sale to Synovus pursuant to this Agreement under applicable securities or “blue sky” laws of the states of the United States or obtain exemption therefrom, and shall provide evidence of any such action so taken to Synvous on
or prior to the Closing Date. From and after the 8-K Filing, the Company hereby acknowledges that Synovus shall not be in possession of any material nonpublic information received from the Company, any of its Subsidiaries or any of their respective
officers, directors, employees or agents. The Company shall not, and shall cause each of its Subsidiaries and each of their respective officers, directors, employees and agents not to, provide Synovus with any material nonpublic information
regarding the Company or any of its Subsidiaries from and after the 8-K Filing without the express written consent of Synvous. Synovus shall not have any liability to the Company, its Subsidiaries or any of their respective officers, directors,
employees, shareholders or agents for any such disclosure. 
 (c) The Company shall ensure that each of the following reports are available
at either www.sec.gov or www.bankofnc.com: (i) within ten days after the filing thereof with the SEC, a copy of its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, its proxy statements and any Current Reports on Form 8-K; and
(ii) within one day after release, copies of all press releases issued by the Company or any of its Subsidiaries. 
 (d) Subject to the
foregoing, neither the Company nor Synovus shall issue any press releases or any other public statements with respect to the Transactions; provided, however, that each party shall be entitled, without the prior approval of the other party, to make
any press release or other public disclosure with respect to the Transactions as is required by applicable law (provided that any such press release or other public disclosure shall be subject to prior review and comment by the other party).

 (e) The Company shall make all necessary filings with the NASDAQ Capital Market as promptly as possible after the date hereof in order for
the Securities to be authorized for quotation and listed on the NASDAQ Capital Market and shall provide evidence of such filings to Synovus. 
 3.7 Use of Proceeds. The Company intends to use the net proceeds from the sale of the Securities for working capital, to fund future loan growth, and general corporate purposes. 
 3.8 Taking of Necessary Action. Subject to the terms and conditions hereof, (i) each of the parties hereto agrees to use all reasonable best
efforts promptly to take or cause to be taken all action and promptly to do or cause to be done all things necessary, 

  

 8 

 
proper or advisable under applicable laws and regulations to consummate and make effective the Transactions, and (ii) each party shall execute and
deliver both before and after the Closing such further certificates, agreements and other documents and take such other actions as the other party may reasonably request to consummate or implement the Transactions or to evidence such events or
matters. 
 3.9 Certain Restricted Actions. Without the prior written consent of Synovus, the Company shall not take any actions which
directly or indirectly cause Synovus to own of record or beneficially more than 4.9% of the Common Stock or voting power of the Company. 
 ARTICLE IV 
 REGISTRATION RIGHTS 
 4.1 Registration Statement. 
 (a) As promptly as possible after the date hereof, the Company shall
prepare and file with the SEC a registration statement covering the resale of all Registrable Securities for an offering to be made on a continuous basis pursuant to Rule 415 (the “Registration Statement”). The Registration
Statement shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance with the
Securities Act and the Exchange Act). For purposes of this Agreement, “Registrable Securities” means any shares of Common Stock, and any shares of Common Stock of the Company issued as a dividend or other distribution with respect
to, or in exchange for or in replacement of, the shares of Common Stock, in each case, held by any stockholder of the Company from time to time; 
 (b) The Company shall use its reasonable best efforts to cause the Registration Statement to be declared effective by the SEC as promptly as possible after the filing thereof, and shall use its reasonable best efforts to keep the
Registration Statement continuously effective under the Securities Act until the earlier of the date that all Securities covered by such Registration Statement have been sold or can be sold publicly under Rule 144(k). 
 (c) The Company shall notify Synovus in writing promptly (and in any event within two trading days) after receiving notification from the SEC that the
Registration Statement has been declared effective. 
 4.2 Registration Expenses. The Company shall pay all fees and expenses incident
to the performance of or compliance with this Article IV by the Company, including (a) all registration and filing fees and expenses, including those related to filings with the SEC, any trading market, any required filing with the
Financial Industry Regulatory Authority by the transfer agent of the Company, and in connection with applicable state securities or “blue sky” laws, (b) printing expenses (including without limitation expenses of printing certificates
for Registrable Securities), (c) messenger, telephone and delivery expenses, (d) fees and disbursements of counsel for the Company, (e) fees and expenses of all other persons retained by the Company in connection with the consummation
of the Transactions, and (f) all listing fees to be paid by the Company to the trading market. 
  

 9 

 4.3 Indemnification. 
 (a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless Synovus, the officers, directors, partners, members, agents and employees of
Synovus, each Person who controls Synovus (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, partners, members, agents and employees of each such controlling Person, to
the fullest extent permitted by applicable law, from and against any and all losses, liabilities, claims, damages, costs and expenses (“Losses”), as incurred, arising out of or relating to (i) any misrepresentation or breach of
any representation or warranty made by the Company in this Agreement, (ii) any breach of any covenant, agreement or obligation of the Company contained in this Agreement, (iii) any cause of action, suit or claim brought or made against
such Indemnified Party (as defined in Section 4.3(c) below) by a third party (including for these purposes a derivative action brought on behalf of the Company), arising out of or resulting from (x) execution, delivery, performance or
enforcement of this Agreement or (y) the status of Indemnified Party as holder of the Securities or (iv) any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any prospectus or any form of
Company prospectus or in any amendment or supplement thereto or in any Company preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the
statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that (A) such untrue
statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding Synovus furnished in writing to the Company by Synovus for use therein, or to the extent that such information relates to Synovus or
Synovus’ proposed method of distribution of Registrable Securities and was reviewed and expressly approved by Synovus expressly for use in the Registration Statement, or (B) with respect to any prospectus, if the untrue statement or
omission of material fact contained in such prospectus was corrected on a timely basis in the prospectus, as then amended or supplemented, if such corrected prospectus was timely made available by the Company to Synovus, and Synovus was advised in
writing not to use the incorrect prospectus prior to the use giving rise to Losses. 
 (b) Indemnification by Synovus. Synovus shall
indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses arising solely out of any untrue statement of a material fact contained in the Registration Statement, any
prospectus, or any form of prospectus, or in any amendment or supplement thereto, or arising out of or relating to any omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any
prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, but only to the extent that such untrue statement or omission is contained in any information so furnished by
Synovus in writing to the Company specifically for inclusion in such Registration Statement or such prospectus, or to the extent that such information relates to Synovus or Synovus’ proposed method of distribution of Registrable Securities and
was reviewed and expressly approved by Synovus expressly for use in the Registration Statement, such prospectus or such form of prospectus or in any amendment or supplement thereto. In no event shall the liability of Synovus hereunder be greater in
amount than the dollar amount of the net proceeds (after discounts and commissions but before expenses) received by Synovus upon the sale of the Registrable Securities giving rise to such indemnification obligation. 
  

 10 

 (c) Conduct of Indemnification Proceedings. If any proceeding shall be brought or asserted against
any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying
Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof; provided, that the failure of any
Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction
(which determination is not subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party. 
 An Indemnified Party shall have the right to employ separate counsel in any such proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such
Indemnified Party or Parties unless: (i) the Indemnifying Party has agreed in writing to pay such fees and expenses; (ii) the Indemnifying Party shall have failed promptly to assume the defense of such proceeding and to employ counsel
reasonably satisfactory to such Indemnified Party in any such proceeding; or (iii) the named parties to any such proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified
Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party
in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of separate counsel shall be at the
expense of the Indemnifying Party). It being understood, however, that the Indemnifying Party shall not, in connection with any one such proceeding (including separate proceedings that have been or will be consolidated before a single judge) be
liable for the fees and expenses of more than one separate firm of attorneys at any time for all Indemnified Parties, which firm shall be appointed by a majority of the Indemnified Parties. The Indemnifying Party shall not be liable for any
settlement of any such proceeding effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending
proceeding in respect of which any Indemnified Party is a party, unless such settlement (x) includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such proceeding, and
(y) does not impose equitable remedies or material obligations on the Indemnified Party. 
 (d) Contribution. If a claim for
indemnification under Section 4.3(a) or (b) is unavailable to an Indemnified Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount
paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that
resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified 

  

 11 

 
Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material
fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section 4.3(c), any reasonable
attorneys’ or other reasonable fees or expenses incurred by such party in connection with any proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was
available to such party in accordance with its terms. 
 The parties hereto agree that it would not be just and equitable if contribution
pursuant to this Section 4.3(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the
provisions of this Section 4.3(d), Synovus shall not be required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by Synovus from the sale of the Registrable Securities subject to the
proceeding exceeds the amount of any damages that Synovus has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
 The indemnity and contribution agreements contained in this Section 4.3(d) are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties. 
 ARTICLE V 
 CLOSING CONDITIONS 
 5.1 Conditions of Purchase at Closing. The obligation of Synovus hereunder to purchase the Securities is subject to the satisfaction, at or before
the Closing, of each of the following conditions, provided that such conditions are for Synovus’s individual and sole benefit and may be waived by Synovus at any time in Synovus’s sole discretion: 
 (a) Delivery of Securities. The Company shall have delivered to Synovus duly executed certificates representing the Securities for the number of
shares of Common Stock being purchased by Synovus, registered in Synovus’s name. 
 (b) Listing. The Common Stock shall be
authorized for quotation and listed on the NASDAQ Capital Market and trading in the Common Stock (or on the NASDAQ Capital Market generally) shall not have been suspended by the SEC or the NASDAQ Capital Market. 
 (c) Representations and Warranties True; Covenants Performed. The representations and warranties of the Company shall be true and correct as of
the date when made and as of the Closing Date as though made at that time, and the Company shall have performed, satisfied and complied with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied
with by the Company at or prior to the Closing Date. 
  

 12 

 (d) No Adverse Law, Action or Decision or Injunction. There shall not be in effect any law or any
order, decree or injunction of a Governmental Entity of competent jurisdiction that enjoins or prohibits consummation of the Transactions. 
 (e) No Material Adverse Change. There shall have been no material adverse changes and no material adverse developments in the business, properties, operations, prospects, financial condition or results of operations of the Company
and its Subsidiaries, taken as a whole, since September 30, 2007, and no information that is materially adverse to the Company and of which Synovus is not currently aware shall come to the attention of Synovus. 
 (f) Regulatory Approvals. All material permits, consents, authorizations, orders, approvals and filings and registrations, if any, required under
any federal, state or foreign law, rule or regulation for or in connection with the execution and delivery of this Agreement and the consummation by the parties hereto of the Transaction shall have been obtained or made. 
 (g) Corporate Approvals. Synovus shall have received a copy of the resolutions, duly adopted by the Board of Directors of the Company, which shall
be in full force and effect at the time of the Closing, authorizing the execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the Transactions, certified as such by the Secretary or Assistant
Secretary of the Company, and such other documents Synovus reasonably requests in connection with the Closing. 
 ARTICLE VI 
 MISCELLANEOUS 
 6.1 Termination. This Agreement may be terminated by the Company or Synovus, by written notice to the other parties, if the Closing has not been consummated by the 45th business day following the date of this Agreement; provided that no such termination will affect the right of any party to sue for any breach by the other party (or parties).

 6.2 Fees and Expenses. Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all
transfer agent fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance of the Securities. 
 6.3
Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and Synovus or, in the case of a waiver, by the party against whom enforcement of
any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. 
  

 13 

 6.4 Remedies. In addition to being entitled to exercise all rights provided herein or granted by
law, including recovery of damages, Synovus and the Company will be entitled to seek an injunction or injunctions or seek specific performance to prevent breaches of this Agreement. The parties agree that monetary damages may not be adequate
compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agrees to waive in any action for specific performance of any such obligation (other than in connection with any action for
temporary restraining order) the defense that a remedy at law would be adequate. 
 6.5 Survival. All of the representations,
warranties, agreements and covenants set forth in this Agreement shall survive the Closing indefinitely; provided that, the representations and warranties contained in Sections 2.5, 2.6, 2.7, 2.8, 2.9 and 2.10 shall survive for a period of three
(3) years after the Closing Date; provided further that, with respect to the representations and warranties contained in Sections 2.5, 2.6, 2.7, 2.8, 2.9 and 2.10, if prior to 11:59 p.m., Eastern time, on the last day such three year period, a
party shall have been properly notified of a claim for indemnity and such claim shall not have been finally resolved or disposed of at such date, such claim shall continue to survive and shall remain a basis for indemnity hereunder until such claim
is finally resolved or disposed of in accordance with the terms hereof. Moreover, none of the representations and warranties made by the Company herein shall act as a waiver of any rights or remedies Synovus may have under applicable U.S. federal or
state securities laws. 
 6.6 Entire Agreement; Third Party Beneficiaries. This Agreement and the documents described herein or
delivered pursuant hereto set forth the entire agreement between the parties hereto with respect to the Transactions, and are not intended to and shall not confer upon any person other than the parties hereto any rights or remedies hereunder.

 6.7 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to constitute an
original, but all of which together shall constitute one and the same document. 
 6.8 Governing Law. This Agreement shall be governed
by, and interpreted in accordance with, the laws of the State of Georgia, without giving effect to the conflict of law principles thereof. 
 6.9 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder. Synovus
may assign or transfer the Securities pursuant to the terms of this Agreement and of such Securities, or assign Synovus’s rights hereunder to any other person or entity who purchases the Securities from Synvous. In addition, notwithstanding
anything to the contrary set forth in this Agreement, the Securities may be pledged and all rights of Synovus under this Agreement may be assigned, without further consent of the Company, to a bona fide pledgee. 
  

 14 

 6.10 Consent to Jurisdiction; WAIVER OF JURY TRIAL. Each of the parties hereto (a) consents
to submit itself to the personal jurisdiction of any Federal or state court located in Atlanta, Georgia in the event any dispute arises out of this Agreement or the Transactions, (b) agrees that it will not attempt to deny or defeat such
personal jurisdiction by motion or other request for leave from any such court and (c) agrees that it will not bring any action relating to this Agreement or the Transactions in any court other than a Federal or state court located in Atlanta,
Georgia. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS. 
 6.11 Severability. If any provision of this Agreement is determined to be invalid, illegal, or unenforceable, the remaining provisions of this
Agreement shall remain in full force and effect; provided that the economic and legal substance of, any of the Transactions is not affected in any manner materially adverse to any party. In the event of any such determination, the parties agree to
negotiate in good faith to modify this Agreement to fulfill as closely as possible the original intent and purpose hereof. To the extent permitted by law, the parties hereby to the same extent waive any provision of law that renders any provision
hereof prohibited or unenforceable in any respect. 
 6.12 Headings. The headings of Articles and Sections contained in this Agreement
are for reference purposes only and are not part of this Agreement. 
 6.13 No Presumption. If any claim is made by a party relating
to any conflict, omission or ambiguity in this Agreement, no presumption or burden of proof or persuasion shall be implied by virtue of the fact that this Agreement was prepared by or at the request of a particular party or its counsel. 

[SIGNATURE PAGES TO FOLLOW] 
  

 15 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed
by their respective authorized signatories as of the date first indicated above. 
  

			
	BNC BANCORP
		
	By:	 	 /s/ David B. Spencer

	Name:	 	David B. Spencer
	Title:	 	EVP and CFO
	
	SYNOVUS FINANCIAL CORP.
		
	By:	 	 /s/ Thomas J. Prescott

	Name:	 	Thomas J. Prescott
	Title:	 	Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]